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1. Preface 
 
1.1 Abbreviations 
ADT androgen deprivation therapy  
AR androgen receptor 
ARCON accelerated radiotherapy with carbogen and nicotinamide 
ARE androgen responsive element 
ATM ataxia telangiectasia mutated  
ATR ataxia telangiectasia and rad3 related protein  
CCN cyclin 
CDK cyclin dependent kinase 
CT computerized tomography  
DHT dihydrotestosterone  
DNA-PKcs DNA-dependent protein kinase, catalytic subunit  
DSB double strand break 
EGFR epithelial growth factor receptor 
EMT epithelial to mesenchymal transition  
GEO gene expression omnibus 
Gn-phase gap phase 
GnRH gonadotropin-releasing hormone  
GO gene ontology  
HAT histone acetyltransferase  
HDAC histone deacetylase  
HG-PIN high-grade prostatic intraepithelial neoplasia 
HIF1 hypoxia inducible factor 1 
HIF1α HIF1, alpha subunit 
HR homologous recombination  
HRE hypoxia responsive element 
HSP heat shock protein  
IMRT intensity modified external beam radiotherapy  
LET linear energy transfer  
LIMMA Linear Models for Microarray data  
MIN microsatellite instability  
M-phase mitosis (phase) 
MRI magnetic resonance imaging 
mTOR mammalian target of rapamycin 
NHEJ non-homologous end joining  
OER oxygen enhancement ratio  
ORP open retropubic prostatectomy  
PHD prolyl hydroxylase  
pO2 oxygen partial pressure  
PSA prostate specific antigen 
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qRT PCR quantitative real time polymerase chain reaction  
RALP robot-assisted laparoscopic prostatectomy  
RB1 retinoblastoma protein 
ROS reactive oxygen species 
SAM-GS significance analysis of microarrays for gene sets  
S-phase synthesis phase 
SSB single strand break 
TNM tumor, node, metastasis 
TP53 tumor protein p53 
TUR-P transurethral resection of the prostate 
VHL von Hippel-Lindau protein 
γH2AX phospho histone H2AX 
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1.3 Aim of the thesis 
Adenocarcinoma of the prostate, in this thesis referred to as prostate cancer, is the sixth 
leading cause of cancer-related deaths in males world-wide and the second-leading in Norway 
(1, 2). After introduction of the prostate-specific antigen (PSA) test, there has been a marked 
increase in prostate cancer incidence, carrying a risk of over-treating indolent cancers (3). 
Thus, both selection of correct treatment intensity and improved strategies to overcome 
treatment resistance are warranted. Hypoxia is associated with poor clinical outcome after 
curatively intended treatment of prostate cancer, and is especially known to induce tumor 
resistance against radiotherapy (4, 5). It is as such both a potential biomarker for disease 
outcome, and a possible target for new treatment combinations and strategies. 
 Importantly, to fully exploit hypoxia as biomarker for disease aggressiveness, and to 
optimize treatment strategies against hypoxic tumors, a better understanding of the molecular 
background of hypoxic prostate cancers is required. Alteration of the transcriptional program 
is an important part of the cellular stress response to hypoxia, partly mediated by activation of 
the hypoxia inducible factor 1 (HIF1) transcription factor (6). Evaluation of gene expression 
can therefore reveal mechanisms by which cells adapt to hypoxia, and give molecular 
information for increased propensity to invade and metastasize. Thus, the overall aim of this 
thesis was to investigate whole-genome transcriptional programs in prostate cancer related to 
hypoxia and treatment interventions. More specifically, we aimed to: 
 Contribute to establishment and implementation of a clinical protocol optimized to 
investigate associations between hypoxia and aggressiveness in prostate cancer 
patients, and analyze the molecular background of hypoxic tumors with focus on 
transcriptional changes. 
 Investigate transcriptional effects by the treatment interventions androgen deprivation 
therapy and the histone deacetylase inhibitor vorinostat, with focus on HIF1 signaling. 
 Evaluate radiosensitization by vorinostat in hypoxic prostate cancer cell lines.
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2. Background 
 
2.1 Hallmarks of cancer 
Carcinogenesis, the creation of cancer, occurs due to mutations in DNA which are 
accumulated over time and passed on to cell progeny (7, 8). These mutations can take form as 
amplifications, deletions, translocations and nucleotide changes. Genes that promote 
carcinogenesis when the activity of their gene product is increased are called oncogenes and 
proto-oncogenes prior to the altering mutation, whereas tumor suppressor genes stimulate 
carcinogenesis when their activity is reduced or lost. In addition, a third class of genes 
involved is stability genes, which normal function is to keep mutations at a minimum (9).   
The process where a malignant tumor develops is characterized by clonal evolution, 
where cells with alterations conferring a growth advantage will dominate the tumor and 
eventually outgrow the other cells (10). These heritable changes result in certain 
characteristics of the cancer cells often referred to as the hallmarks of cancer, a concept 
introduced by Hanahan and Weinberg in 2000 (11) and further developed in 2011 (Figure 1; 
(12)) 
 
Figure 1: The hallmarks of cancer. Adapted from (12), with permission. 
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It is assumed that the acquisition of cancer hallmarks is made possible by two enabling 
characteristics: Genome instability and mutation and tumor promoting inflammation (12). The 
former hallmark can be acquired through disruption of DNA damage sensors or repair genes 
by deleterious mutations, and it has the potential of accelerating the rate of favorable 
mutations (12). One example is mutation of the tumor suppressor protein TP53, often referred 
to as the “guardian of the genome”, which normally induces growth arrest or cell death after 
irreversible DNA damage (13). As a result of TP53 mutation, cancer cells may replicate 
damaged DNA and pass the damage on to progeny, which may lead to further genomic 
instability and mutations in the daughter cells. Interestingly, in prostate cancer, TP53 
mutations are more common in advanced stages and it correlates with higher grade and poor 
survival following therapy (14). It is also acknowledged that epigenetic regulation, i.e. 
heritable changes in gene activity not accompanied by changes in DNA sequence, may give 
rise to genomic instability, for instance by epigenetic silencing of the cell cycle regulator 
protein CDKN2A (p16) (15).     
Hanahan and Weinberg state that tumor promoting inflammation may be an enabling 
characteristic of cancer that drive the carcinogenic process by secretion of mutagenic 
chemicals and supplying bioactive molecules in the microenvironment (12). Conversely, 
tumor cells must evade destruction by the host immune system, which for instance can be 
performed through active secretion of immunosuppressive factors (12).  
Genome instability and mutations may also be a consequence of tumor hypoxia. This, 
together with deregulating cellular energetics, inducing angiogenesis, resisting cell death and 
activating invasion and metastasis are hallmarks of particular relevance for hypoxia-related 
aggressiveness, and will be further described in the hypoxia section. Moreover, enabling 
replicative immortality, sustaining proliferative signaling, and evading growth suppressors are 
hallmarks related to rapid cell proliferation, which is another characteristic of prostate cancer 
aggressiveness (16, 17). Control of the cell cycle is central in regulating cell proliferation and 
in maintenance of tissue homeostasis, and this will be covered in the following section.  
 
2.1.1 The cell cycle and tumor cell proliferation 
Before mitosis where the cell divides, it must replicate its DNA. The cell cycle describes the 
order of these events and consists of two phases, interphase and mitosis (M-phase), where 
interphase is further sub-divided into the G1-, S- and G2-phases (Figure 2; (18)).  
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Figure 2: Simplified overview of the cell cycle including checkpoints and regulatory 
proteins. Adapted from Wikipedia. Abbreviations: Gn: Gap phases, R: Restriction point, S: 
Synthesis phase, M: Mitosis, I: Interphase, CDK: Cyclin-dependent kinase, CCN: Cyclin, P: 
Phosphate group. 
 
In S-phase (synthesis phase), DNA is replicated to produce two identical sister 
chromatids per chromosome. The sister chromatids are split by the spindle apparatus during 
M-phase. Between these two phases are the gap phases; G1 between M- and S-phase and G2 
between S- and M-phase. Progression through the cell cycle is strictly regulated through the 
activity of proteins termed cyclins (CCNs) and cyclin-dependent kinases (CDKs). As the 
name implies, the expression of cyclins will change during the cell cycle, and each cyclin has 
a role in a specific phase of the cycle (Figure 2). After hetero-dimerization of a cyclin to a 
CDK, the CDK phosphorylates serine and threonine residues on target proteins, thus changing 
their function to allow cell cycle progression. This activity can be further enhanced or 
attenuated by phosphorylation or dephosphorylation of the CDKs by regulatory enzymes (19). 
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To counteract the potentially deleterious consequences of replication or chromosome 
segregation with damaged DNA, cells have a checkpoint apparatus located at G1/S and G2/M 
transitions (20). In addition, there is a spindle assembly checkpoint in M-phase ensuring that 
anaphase does not occur prematurely (21), and mechanisms for a delay of S-phase 
progression (22) (Figure 2).  
Cell cycle control is vital to tissue integrity, including the decision to enter interphase 
from a non-proliferative, quiescent state (G0). The decision to enter the cell cycle from G0 is 
the result of a balance between stimulating and inhibiting factors. A balance in favor of 
stimulating factors (mitogens) will result in upregulation of cyclin D, which dimerizes with 
CDKs 4 and 6 (Figure 2). This leads to phosphorylation of the retinoblastoma protein (RB1) 
and release of the transcription factor E2F. E2F stimulates the transcription of cyclin E 
(CCNE), which acts in a positive feedback loop on RB1, leading to augmentation of free E2F. 
The cell has now passed the so-called restriction point in G1 (Figure 2), where it is bound to 
enter S-phase despite disappearance of mitogenic signaling (18).  
Control over the restriction point is related to the cancer hallmarks sustaining 
proliferative signaling and evading growth suppressants. Proliferative signaling may be 
conveyed through upregulation of receptors that receive proliferation signals from 
surrounding tissues, making them sensitive to low levels of ligands, or by mutations that 
reduce the ligand specificity. Alternatively, the cells may have mutations in signaling 
cascades downstream of the receptors that render them “always on” (12), or they may produce 
the ligand themselves (23). In prostate cancer such changes are commonly found in the 
androgen receptor (AR) or its downstream proteins (24). With regard to the restriction point, 
AR has been found to upregulate cyclin D (CCND) through the mammalian target of 
rapamycin (mTOR) pathway, thus stimulating G1/S transition (25).  
Conversely, proliferation, or passing of the restriction point, can be hindered by 
growth suppressants, and evasion of growth suppressive signaling is one of the cancer 
hallmarks. Non-transformed cells are often sensitive to growth inhibitory signaling (Figure 2) 
by for instance transforming growth factor, beta 1 (TGFβ1). Loss of sensitivity to such 
inhibitory signaling is associated with the carcinogenic process (12, 26). 
In culture, non-malignant cells can only divide a limited number of times (27), 
whereas cancer cells have the ability to divide indefinitely (12). This replicative immortality 
characteristic is attributed to the function of telomerases, which are enzymes that extend the 
telomers, i.e. the ends of the DNA molecule. Telomerases counteract the shortening of the 
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DNA strands that normally occurs at each cell division and leads to cell senescence, i.e. stop 
in proliferation capacity or clonogenic death (12).  
 
The DNA damage response in relation to radiobiology  
The DNA damage response consists of a network of interacting pathways committed to sense 
DNA damage and elicit counteracting effects (Figure 3, (28)). Sources of DNA damage can 
be endogenous due to replication stress or production of reactive oxygen species (ROS) in 
metabolic processes, or exogenous by ionizing radiation, ultraviolet light or chemotherapy 
(Figure 3). DNA damage which progresses to progeny cells can give rise to cancer 
development or cell death, and the DNA damage response is as such a tightly regulated 
system (29). 
 
 
 
Figure 3: The DNA damage response divided into sensors, transducers and effectors with 
different effects listed. Adapted from (28), with permission. 
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Radiotherapy, where ionizing radiation is utilized to induce DNA damage, will elicit 
the DNA damage response. A radiation dose of 1 Gy causes approximately 20-40 double 
strand breaks (DSBs) (30). DSBs, which are the most lethal forms of DNA damage, can lead 
to disastrous changes in the DNA molecule, such as loss of an entire chromosome arm. In 
DSB repair, one of the first events is the phosphorylation of hundreds of proteins, with one of 
the earliest being histone H2AX, forming gamma H2AX (γH2AX). Three related kinases are 
known to be capable of phosphorylating H2AX, namely ataxia telangiectasia mutated (ATM), 
DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) and ataxia telangiectasia and 
Rad3-related protein (ATR) (30). ATM is dependent on the DNA damage sensor MRN, 
consisting of the nuclease MRE11, the DNA-binding protein RAD50 and the ATM-
interacting NBS1 in the process of creating γH2AX around DSB foci (30).  
Subsequently, ATM may phosphorylate the TP53-MDM2 protein complex. This leads 
to dissociation and transactivation activity of TP53, which in turn may induce G1 arrest or in 
some rapidly proliferating tissues apoptosis (30). ATM and ATR may also phosphorylate the 
checkpoint kinases CHK1 and CHK2. This may lead to cell cycle delay in S-phase and arrest 
in G2 phase due to inactivation of CCN/CDK complexes through phosphorylation of CDC25 
(30), allowing time for DNA repair. Due to the frequent mutated status of TP53, and thereby 
impaired capability of G1 arrest, following ionizing radiation cancer cells largely depend on 
the G2/M checkpoint in order to repair DNA damage prior to mitosis (31).   
The two main pathways for repair of DSBs are homologous recombination (HR) and 
non-homologous end joining (NHEJ), where HR is only achievable when sister chromatids 
are available in S- and G2-phase (Figure 4, (30)). Both HR and NHEJ utilize several proteins 
in the repair process (Figure 4). HR uses an undamaged sister chromatid as template for 
repair, and is as such error-free, whereas NHEJ will lead to ligation of the DNA ends after 
end-processing, making room for mutations. Choice of which pathway to use in the S- and 
G2-phases is thought to be determined by the competitive binding of the MRN complex and 
the KU proteins (XRCC5 and XRCC6) to the DSB site (Figure 4). The KU proteins are 
important DSB sensors which recruit the DNA-PKcs (30). If DNA repair is not successful, 
cells can execute the apoptotic process, i.e. undergo programmed cell death. 
Other DNA damage forms induced by ionizing radiation include single strand breaks 
(SSBs), approximately 1000 breaks per Gy, and damage to DNA bases, with more than 1000 
in number per Gy (30). If a SSB is situated close to a DNA base damage, the SSB may be 
converted to DSB in the repair process of the base damage. In addition, induction of SSBs 
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during DNA replication can lead to collapse of the replication fork and the creation of a 
single-ended DSB requiring HR (30). 
 
 
Figure 4: Simplified overview of the two main pathways of DNA double strand break (DSB) 
repair: Non-homologous end joining (NHEJ) and homologous recombination (HR). In the 
process of NHEJ the DSB is recognized by the KU proteins and DNA-PKcs. This leads to 
phosphorylation (P) and recruitment of repair proteins with subsequent ligation of the DNA 
strand (left). In HR the DSB is recognized by the MRN complex (NBS1, RAD50 and 
MRE11). The DNA ends are resected and following recruitment of DNA repair proteins, a 
homologous region on a sister chromatid is used as template resulting in error-free repair 
(right). Image and legend adapted from (32), with permission. 
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In radiotherapy, the goal is to target the tumor with ionizing radiation while sparing 
surrounding normal tissue. This can in part be achieved through conforming of the radiation 
dose to the tumor. In addition, radiotherapy with curative intent is often given in 2 Gy daily 
fractions, which counteracts long-term side effects from normal tissues, e.g. the rectal wall, 
and allows delivery of a greater total dose to the irradiated field (30). Other strategies to 
increase disease control include concurrent treatment with chemotherapy, which may 
contribute in several ways, among them through spatial cooperation, where chemotherapy 
removes tumor cells in other compartments than covered by radiation. Enhancement of tumor 
response is another mechanism, due to inhibited DNA repair and shrinkage of the tumor (33). 
In recent years, radiotherapy combined with targeted therapeutics such as antagonists to the 
epidermal growth factor receptor (EGFR) have gained increasing attention (34). 
In general, in addition to tumor size, there are three main phenotypes determining the 
radiosensitivity of a tumor: Intrinsic radiosensitivity, repopulation between fractions and 
tumor hypoxia (30). The intrinsic radiosensitivity shows great variation between different 
cancers and is dependent on alterations in cell cycle checkpoint signaling, apoptosis 
mechanisms and DNA repair pathways. Repopulation means the ability a tumor has to 
proliferate between treatment fractions. A high repopulation rate is regarded as a negative 
prognostic factor (30), and a possible strategy to counteract this is by accelerating the 
radiotherapy regime, i.e. give the patient more than five fractions of two Gy per week (30). 
Tumor hypoxia plays fundamental roles in cancer biology in general, including response to 
ionizing radiation, and is covered in the following section. 
 
2.1.2 Tumor hypoxia  
In 1955, after investigation of the histological architecture of lung tumors, Thomlinson and 
Gray proposed that hypoxia may occur in tumors in vivo (35). Since then it has become 
evident that hypoxia is a common feature of most solid tumors, often associated with 
increased cancer aggressiveness (36). Hypoxia in cancer biology is often defined as an 
interstitial oxygen partial pressure (pO2) below 2 %, compared to a pO2 of 2-9 % in most 
normal tissues (37). Other oxygen levels are, however, also used, and the hypoxia term is not 
well defined (38). Related characteristics of the microenvironment are nutrient deprivation, 
low extracellular pH and high interstitial fluid pressure (39). 
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Development of the hypoxic phenotype  
Tumor hypoxia is caused by an imbalance between oxygen demand and supply. The 
oxygen demand of the tumor cells is increased due to their high proliferation activity, whereas 
a poor vascular network leads to an insufficient oxygen supply. Angiogenesis, the process 
where new blood vessels form from pre-existing vessels, is normally a balanced process 
consisting of favoring and opposing signaling, controlled by angiogenic proteins like VEGFA 
and angiostatin, respectively (40). To maintain oxygen delivery, a growing tumor must induce 
the generation of its own vascular network. Acquisition of this ability is often referred to as 
the angiogenic switch (41). Thus, in the development of a tumor, stimulation of existing 
capillaries to divide and infiltrate a growing neoplasm is a crucial step, and inducing 
angiogenesis is one of the cancer hallmarks as defined by Hanahan and Weinberg (12). 
However, the tumor-induced blood vessel network is often highly irregular with tortuous 
vessels, blind ends and presence of arterio-venous shunts (42). This can lead to sluggish blood 
flow and episodes of thrombosis causing abrupt changes in blood flow (Figure 5) giving rise 
to acute, or perfusion-limited, hypoxia (43). Causes of acute hypoxia can dissolve, and 
thereafter re-emerge – creating cycles of acute hypoxia episodes, often referred to as cyclic 
hypoxia. Oxygen has a limited diffusion capacity in a tissue, estimated to approximately 145 
μm (37) and hypoxia developed by limited diffusion of oxygen due to long distance between 
functional vessels and cells, is referred to as diffusion-limited, or chronic, hypoxia. 
 
 
 
Figure 5: Vasculature in normal tissue and in a hypoxic tumor. Abbreviation: AV Shunt: 
arterio-venous shunt. From (42), with permission. 
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For the cells to survive at low oxygen levels, adaptation mechanisms have to be 
activated. Thus, the hypoxic microenvironment exerts a selection pressure on the tumor cells, 
resulting in survival of cells with advantageous traits. For instance, it has been shown that 
cyclic hypoxia will select cells with insensitivity to mitochondria-mediated apoptosis (44). 
Additionally, Graeber and co-workers demonstrated that hypoxia enriches for cells with 
mutations in TP53 (45). This may be an underlying mechanism for the cancer hallmark 
resisting cell death (12).  
Another important survival mechanism under hypoxia is the ability to reprogram 
metabolism to allow production of ATP despite limited supply of oxygen. This can be 
achieved through conversion of glucose to lactate. One of the mechanisms involved is 
stabilization of the alpha subunit of the transcription factor HIF1 (HIF1α). In turn, this leads 
to increased transcription of glycolytic enzymes, increased glycolytic flux, and thereby 
sustained ATP production under hypoxic conditions (46).  
 
 
Figure 6: Cellular consequences of hypoxia, with relevant oxygen partial pressures (pO2) in 
mmHg on a logarithmic scale, where 7.5 mmHg ≈ 1kPa ≈ 1% O2. From (38), with permission. 
 
The observation of increased glycolytic flux in cancer is not new, as Otto Warburg 
described this already in 1924, relating it to mitochondrial dysfunction (47). In later years it 
has become clear that a reprogramming of metabolism can occur in cancer cells irrespective 
of hypoxia, thus, deranged energetics is now regarded as one of the cancer hallmarks (12). In 
terms of ATP production, converting glucose to lactate is less efficient than forming pyruvate 
with subsequent oxidative phosphorylation (12). However, potential benefits of such a 
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reprogramming may be a high availability of metabolism intermediates that can be converted 
to amino acids, nucleotides and lipids needed for proliferation (48) and increased resistance 
against rapid fluctuations in the oxygen level that would otherwise impair energy production 
and lead to production of ROS (49). Interestingly, AR, which is utmost important for 
proliferation and survival of prostate cancer cells, has a stimulatory effect on regulatory, 
glycolytic enzymes (50). 
 
Hypoxia and radioresistance  
Already in 1909, Gottwald Schwarz observed that inducing anemia would make a tissue more 
radioresistant (51), and in 1953 had Gray and colleagues established that radiation of anoxic 
tissues caused less damage than radiation under well oxygenated conditions (52). The causal 
relationship between tumor hypoxia and reduced cell kill by radiation is well established, and 
tumor hypoxia is an adverse factor in radiotherapy of several cancer forms (53-57), including 
prostate cancer (4, 5).  
The radiation dose needed to reduce the clonogenic capacity to a certain level under 
hypoxic as compared to normoxic conditions is termed the oxygen enhancement ratio (OER) 
and is typically reported to be between 2.7 and 3.0 (58). This means that approximately 3 
times higher radiation dose is needed to kill the same fraction of cells in a hypoxic than a 
normoxic milieu. However, OER will vary based both on the linear energy transfer (LET) of 
the radiation (30), i.e. the energy the radiation particles transfer to the environment per 
distance, and on the oxygen level. Whereas hypoxia important for cancer biology is often 
regarded as pO2 below 2 %, the radiobiologically relevant hypoxia comes into play at lower 
concentrations, typically below 0.7 % (58). 
The mechanism underlying the higher radiosensitivity of cells in the presence of 
oxygen is explained through the oxygen fixation hypothesis, proposed in the 1950s (30). 
Radiation causes either a direct damage to the DNA strand, or damages DNA indirectly 
through ionization of other molecules, mostly water, which again ionizes the DNA strand. 
Following this, oxygen fixes the DNA damage by reacting with free radicals in DNA, making 
the damage irreparable by the DNA repair machinery (30). Moreover, the induced damage 
could be more extensive under oxic conditions, due to increased generation of radicals from 
free oxygen in addition to radicals from the water molecule.   
Several attempts have been made to counteract the reduced efficiency of radiation in 
hypoxic tumors (58). One way is to diminish chronic hypoxia by letting the patient breathe 
oxygen enriched gases like carbogen (mixture of 95 % oxygen and 5 % CO2) or hyperbaric 
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oxygen to increase the blood oxygen level (59, 60). In the accelerated radiotherapy with 
carbogen and nicotinamide (ARCON) study on head and neck cancer, nicotinamide was also 
added, since this drug has been demonstrated to reduce the opening and closing of blood 
vessels and hereby cyclic hypoxia due to fluctuations in blood flow (61, 62). In a phase three 
trial, an increased regional control rate was seen for patients on ARCON treatment compared 
with the control arm with accelerated radiotherapy alone. In a sub-analysis, hypoxic tumors 
showed a benefit from ARCON, whereas non-hypoxic did not (63). Another strategy for 
combating hypoxia-induced radioresistance is the use of chemical modifiers that mimic 
oxygen. This field has evolved since the first experiments by Adams in 1963 (60, 64). Today, 
the drug nimorazole is included in radiotherapy regimens for head and neck cancer in some 
hospitals, among them our institution, and has been shown to increase both the local control 
rate and the disease-specific survival following radiotherapy of patients with hypoxic head 
and neck tumors (65).  
 
Hypoxia and genetic instability 
Hypoxia is thought to affect genetic stability in several ways and has been linked to genome 
instability and mutation, one of the enabling hallmarks of cancer (12, 66, 67). As mentioned 
can hypoxia increase the prevalence of TP53-mutated cancer cells (45), resulting in 
deregulated genomic control through reduced cell cycle checkpoint and apoptotic abilities.  
Studies have also shown increased rate of spontaneous DNA mutations in cells 
exposed to hypoxia, which could be due to induction of intrachromosomal fragile sites (68). 
Furthermore, cyclic hypoxia, where episodes of acute hypoxia are followed by reoxygenation 
and massive outburst of free radicals, may damage DNA. DNA repair enzymes are found to 
be downregulated under hypoxia, especially enzymes important for HR, such as RAD51, 
resulting in increased chromosomal instability (66). Hypoxia has also been associated with 
another mechanisms for DNA instability, namely microsatellite instability (MIN) (66). MIN 
is caused by defective mismatch repair, one of the DNA repair pathways, which is important 
for repair of base substitutions and misalignments occurring during DNA replication (66).  
 
Hypoxia, invasion and metastasis  
The main cause of death from cancer is by metastasis to other organs (69), and there is a 
growing body of pre-clinical evidence and clinical associations linking hypoxia to higher 
invasive potential and ability to metastasize (36). The underlying mechanisms have not been 
resolved, and seem to differ across tumors. However, both hypoxia induced genomic 
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instability and activation of signaling pathways through regulation of gene and protein levels 
and activity may play a role (67). Activating invasion and metastasis is one of the cancer 
hallmarks (12), and for carcinoma cells it starts by invasion through the basement membrane 
into the surrounding stroma. Subsequently, cancer cells must acquire mutations and 
epigenetic alterations which allow them to intravasate, survive in the blood or lymph 
circulation, arrest at a distant organ site and extravasate into a new tissue (Figure 7, (69)). At 
these steps, hypoxia has shown to be a key player (70). 
 
 
Figure 7: The process of invasion and metastasis. From (69), with permission. 
 
 A model for the capacity to invade surrounding stroma is the epithelial to 
mesenchymal transition (EMT), where cancer cells lose their adherent, epithelial properties 
and are converted to invasive, mesenchymal-like cells. Hypoxia is known to upregulate 
transcription factors that facilitate this transition, such as TWIST1 and SNA1, and enzymes 
that modify collagen fibers such as LOX (70). Interestingly, animal studies have shown that 
cyclic, but not chronic hypoxia, enhanced spontaneous lung metastasis in xenograft-bearing 
mice (71), but it is still an unresolved question whether cyclic or chronic hypoxia has the 
strongest influence on the metastatic phenotype (72, 73). 
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2.2 Transcriptional regulation of cancer hallmarks 
The central dogma of molecular biology states that DNA is transcribed to RNA which is 
translated to protein (74). An important regulatory step in this pathway is control of gene 
transcription, i.e. the decision of which parts of DNA that shall be transcribed to RNA, and 
when this should occur. All somatic cells in the body contain the same DNA, thus, 
transcriptional regulation forms the basis of differentiated cellular function and adaptation of 
cells and organisms to different environments and demands (19). Some of the genomic 
alterations in cancer lead to aberrant gene expression and regulation, which drive 
development of cancer hallmarks and tumor progression.  
The introduction of global gene expression analysis by microarray techniques and, 
recently, RNA sequencing has revealed novel insight into how the cancer hallmarks associate 
with specific changes in the transcriptional program. The use of these techniques for analysis 
at the DNA level has shown that cancers are highly heterogeneous at the genomic level. 
However, recently Markert and co-workers analyzed a set of gene expression profiles and 
revealed two common prognostic transcriptional programs across several types of cancers, 
including prostate cancer, i.e. proliferation and tissue remodeling (16). The tissue remodeling 
transcriptional program was related to hypoxia and associated with HIF1 activation (16). In 
this thesis, we focused on regulation of gene expression by gene regulatory proteins and 
epigenetic mechanisms through histone acetylation status. In addition, the transcriptional 
program in prostate cancer was examined on a whole-genome basis in relation to hypoxia and 
the proliferation marker Ki67. 
 
2.2.1 Gene regulatory proteins 
Gene regulatory proteins, hereafter referred to as transcription factors, bind to DNA in the 
promotor region of their target genes and hereby affect the amount of transcription, working 
either as transcription activators or repressors (19). A single transcription factor has the ability 
to affect transcription of several genes. Conversely, the transcription of a single gene may be 
influenced by several transcription factors (75). A transcription factor of particular importance 
for the pathogenesis of prostate cancer is AR, whereas a transcription factor that has been 
shown to play a major role in the regulation of gene expression under hypoxia is HIF1.  
 
The AR transcription factor 
The gene for AR is located on the X-chromosome and is widely expressed in both sexes, 
especially in reproductive tissues. Its main ligand is dihydrotestosterone (DHT), which is the 
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product of intracellular conversion of testosterone by 5alpha-reductase (23). Testosterone, a 
steroid hormone synthesized from cholesterol in the testicular Leydig cells, is transported in 
the blood through binding proteins like sex hormone binding globulin (SHBG).  
The AR-ligand complex binds to androgen-responsive elements in the DNA and alters 
the transcriptional program (Figure 8, (23)). In addition to proliferation and cell cycle 
progression, androgen dependent gene expression induce metabolism, which provide energy 
and availability of biomolecules for prostate cancer carcinogenesis (50). The importance of 
AR in prostate cancer is exemplified by the effect of androgen deprivation therapy (ADT) on 
prostate cancer survival and metabolism, as further discussed in section 2.3.7 under palliative 
treatment modalities for prostate cancer.  
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Figure 8: AR with ligands and co-regulators. The numbers refer to the figure: Testosterone is 
converted to dihydrotestosterone by 5-alpha-reductase (DHT; 1) and binds to AR (2) at the 
ligand-binding domain (LBD). This leads to conformational change of the receptor, 
dissociation of the heat shock protein (HSP) and recruitment of proteins important for 
stabilization and translocation to the nucleus (importin-α, ARA 70, Filamin-A; 3, 4). 
Following dimerization (5), several co-regulators bind to the AR at the N-terminal 
transactivation domain (NTD; 6). The receptor binds to androgen responsive elements (ARE) 
through the DNA binding domain (DBD), which promote recruitment of proteins with histone 
acetyltransferase activity (CBP/p300, P/CAF, SRC/p160), resulting in chromatin remodeling 
and facilitating transcription through TATA binding protein (TBP) and general transcription 
factors (GTF). Non-ligand bound AR can either be shuttled back to the cytoplasm and re-
cycled (7) or be targeted for proteosomal degradation following ubiquitylation by E3 
ubiquitin ligase (8). Figure and legend adapted from (23), with permission.  
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The HIF1 transcription factor 
The hypoxia inducible factors are a set of proteins involved in numerous biological processes. 
The best characterized is HIF1, which consists of two subunits, the oxygen regulated HIF1α 
and the constitutively expressed HIF1β (ARNT) (76). The expression and transactivating 
capabilities of HIF1 is regulated by both oxygen-dependent and -independent mechanisms 
(Fig. 9, 10; (38)). In normoxia prolyl hydroxlase (PHD) will contribute to oxygen dependent 
hydroxylation of HIF1α, which results in binding of the von Hippel-Lindau (VHL) protein to 
HIF1α, followed by degradation. Under hypoxia will the degradation of HIF1α not occur and 
it dimerizes with HIF1β (Fig. 10). The HIF1 complex translocates to the nucleus and binds to 
hypoxia-responsive elements (HREs) on the DNA strand, which leads to alterations of the 
transcriptional program, as shown in Figure 10 and 11.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: HIF1α degradation under 
normoxia. See text for details. Figure 
adapted from (38), with permission. 
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Figure 10: HIF1α regulation. See text for details. Figure modified from (38), with 
permission. 
 
Oxygen independent regulation of HIF1 includes pathways that stimulate proliferation 
such as the PI3K-AKT and RAS-RAF-MEK-MAPK signaling pathways (Figure 10; (77)).  In 
prostate cancer a cross-talk between HIF1 and AR has been investigated. Mabjeesh and co-
workers found that activation of AR by androgens led to increased secretion of epithelial 
growth factor (EGF) and autocrine binding of EGF to EGF receptor (EGFR), which in turn 
stimulated the PI3K-AKT pathway and transcription of HIF1α (Figure 10, (78)). With the 
pivotal role of AR function in mind, this finding suggests that oxygen independent 
mechanisms can be important in prostate cancer.   
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Figure 11: Biological processes and protein expression altered by HIFs. Abbreviated names: 
CAIX, carbonic anhydrase IX; CXCR4, chemokine (C-X-C motif) receptor 4; IGF2, insulin-
like growth factor 2; PDGF, platelet-derived growth factor; PDK1, pyruvate dehydrogenase 
kinase, isoenzyme 1; SDF1α, stromal cell-derived factor 1α; VEGFA, vascular endothelial 
growth factor A. Figure reproduced from (37), with permission. 
 
The alterations of biological processes by HIF1, for instance induction of angiogenesis 
and regulation of pH in response to anaerobic metabolism  (Figure 11), is a part of the cellular 
stress response to hypoxia (37). At the same time, genes encoded by HIFs are involved in 
several processes important for tumor initiation, growth, invasion and metastasis, such as 
modulation of extracellular matrix, motility, proliferation  and inflammatory cell recruitment 
(37), creating associations to several hallmarks of cancer (12). Expression of HIF1α has been 
observed in several cancers, including prostate cancer (6, 79-81), and Zhong and co-workers 
demonstrated an upregulation of HIF1α in prostatic intraepithelial neoplasia as compared to 
adjacent normal glands, pointing to a possible function in early prostate carcinogenesis (81). 
Moreover, high HIF1α expression has been shown to associate with poor outcome of prostate 
cancer patients after both surgery and radiotherapy (80). HIF1 therefore seems to be a 
transcription factor of high importance in prostate cancer (82) 
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2.2.2 Epigenetic modification of DNA by changing histone acetylation status 
The primary unit of chromatin is the nucleosome, which consists of DNA wrapped around a 
histone complex. The histones can be target of chemical modification, in form of acetylation, 
methylation and phosphorylation of the N-terminal ends, which are all important epigenetic 
regulatory mechanisms for gene transcription. Histones with acetylated lysine residues are in 
general associated with a looser chromatin conformation, which allows access to DNA by 
transcription factors and RNA polymerase, thus enhancing gene expression (83). Histone 
acetylation status is a reversible process where enzymes within the classes histone 
acetyltransferase (HAT) and histone deacetylase (HDAC) have opposing actions. The balance 
between these enzymes regulates expression of many genes, and HDACs have also been 
shown to modulate non-histone protein function (Figure 12; (83)). 
Anti-cancer activity of HDAC inhibitors has been investigated in many cancer entities 
both as monotherapy and in combination with chemotherapy and radiation (84). Vorinostat, 
also called suberanilohydroxamic acid or SAHA, inhibits HDAC function through zinc 
chelation and is approved for treatment of cutaneous T cell lymphoma. In addition, the drug 
has shown anti-proliferative and apoptotic effects in vitro and growth suppressive effects in 
vivo in prostate cancer models (85). Vorinostat influences the expression of various genes and 
proteins (Figure 12), and the precise mechanism of action leading to apoptosis, differentiation 
and radiosensitization of cancer cells is not fully elucidated. However, several studies indicate 
that HDAC inhibitors target the oncogenic action of HIF1 (86).  
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Figure 12: Proposed action of vorinostat leading to cell cycle arrest and apoptosis. Vorinostat 
inhibits HDAC activity which leads to increased acetylation of histones and other proteins. 
This affects the chromatin structure, transcription factors, the mitotic spindle apparatus and 
other regulatory proteins such as the chaperone heat shock protein 90 (HSP90). Adapted from 
(87), with permission. 
 
Vorinostat as radiosensitizer 
The limiting factor in radiotherapy is the sensitivity of the surrounding normal tissues and 
thereby the risk of radiation induced morbidity (88). Thus, strategies to improve the 
radiosensitivity of tumor cells without sensitizing normal cells are highly warranted (88). As 
discussed above in section 2.1.2, tumor hypoxia increases the radioresistance and constitutes a 
therapeutic problem in radiotherapy. Treatment with radiosensitizing drugs showing efficacy 
in hypoxic cells could be an option to overcome this problem. Chinnaiyan and co-workers 
found a radiosensitizing effect of vorinostat in the prostate cancer cell line DU 145 under 
normoxia. Mechanistically, concurrent vorinostat and radiation treatment reduced the 
induction of DNA damage proteins RAD51 and DNA-PK, and increased apoptosis as 
compared to radiation alone (89). Recently, a phase 1 trial combining vorinostat with 
palliative pelvic radiotherapy for metastatic colorectal cancer was conducted at our institution 
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(90). In addition, we have shown radiosensitizing effects of vorinostat under normoxic and 
hypoxic conditions in a colorectal cancer xenograft model (91, 92). Vorinostat is therefore a 
candidate for combating hypoxia induced radioresistance in prostate cancer, and was further 
examined in this thesis. 
 
 
2.3 Prostate cancer  
2.3.1 Prostate anatomy and physiology 
The prostate is an exocrine gland and a part of the male accessory sexual organs. It is located 
below the urinary bladder and surrounds the urethra (Figure 13). The function of the prostate 
is to produce an alkaline fluid involved in maturing and nourishing sperm and in dissolving 
the cervical plug. The prostate can be divided into an anterior fibro-muscular stroma, in 
addition to three glandular zones: The peripheral, transitional and central zones (93, 94). Two 
of the main disease entities in the prostate are benign prostatic hyperplasia and prostate 
cancer. Approximately 70 % of prostate cancers arises in the peripheral zone (95).    
 
 
Figure 13. The prostate with surrounding structures. From Wikipedia. 
 
2.3.2 Epidemiology and etiology  
In Norway, 4978 men were diagnosed and 1052 men died from prostate cancer in 2011, 
making the disease the most commonly diagnosed and the second leading cause of cancer-
related death among males (1). Correspondingly, prostate cancer is the second most 
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commonly diagnosed, and the sixth leading cause of cancer-related deaths among males in the 
world (2). Studies of men from USA show that African-Americans have higher incidence and 
mortality from prostate cancer, and men of Asian ethnicity have lower incidence and 
mortality compared to Caucasian men (96). Prostate cancer is primarily a disease of the 
elderly men, with a median age at diagnosis of 72 years in Norway in 2004 (97). The 
mortality has declined since the 1990s, which has been attributed to improved treatment and 
possibly the use of the PSA test (2).  
Lifestyle has been discussed as a possible risk factor of developing prostate cancer, 
with dietary factors such as obesity and high fat consumption as  risks, and intake of soy and 
vegetables such as tomatoes being protective (98). The only established etiological factors, 
however, are age, family history and ethnicity (99, 100). The association between age and 
prostate cancer is not only found in the clinic, but also in autopsy studies where the 
prevalence increases with higher age (101).  
First-degree relatives of prostate cancer patients diagnosed before the age of 60 have 
more than four times the risk of acquiring prostate cancer compared to men without family 
history (99). The contribution of germline genetic alterations is largely unknown, but some 
gene aberrations have been identified as risk carriers, such as mutations in the tumor 
suppressor genes BRCA1 or BRCA2, which has been found to elicit approximately four and 
five times higher risk of prostate cancer compared to wild-type, respectively (99). A recurrent 
somatic mutation is the fusion between TMPRSS2 and members of the ETS gene family, with 
the most frequent aberration being the TMPRRS2-ERG fusion gene (102).  
 
2.3.3 Carcinogenesis, morphology and grading 
The vast majority of prostate cancers have differentiation pattern as adenocarcinoma (103). 
The only accepted precursor is high-grade prostatic intraepithelial neoplasia (HG-PIN), which 
is characterized by hyperplasia of glands, but with retained basal cell layer and without 
invasive properties (104). Prostatic inflammatory atrophy, i.e. atrophic areas where cells 
regenerate in response to unknown cellular damage (105), has also been linked to prostate 
cancer development (106). 
The dominating grading system for prostate cancer in the world today is the Gleason 
score, originally presented by the American pathologist Donald Gleason in 1966, with the 
latest consensus revision performed in 2005 (107). A prostate tumor is assigned a Gleason 
score based on the morphological architecture of the cancerous glands. The score is the sum 
of the two most prevalent Gleason grades in the specimen, where each grade is a number 
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between 1 and 5. A higher score is associated with a more aggressive tumor, and a tumor with 
high Gleason score is in general characterized by poor differentiation, fused glands and 
necrotic areas (107). Prostate cancer is often multi-focal, with different Gleason scores within 
one specimen. There has been international consensus-meetings with goal of defining the 
index or dominating tumor among these (108). In our work, the index tumor was defined as, 
in descending order, the tumor which gave highest pT category, Gleason score or tumor size. 
 
 
Figure 14. The Gleason grading system for prostate cancer. From (107), with permission 
 
2.3.4 Clinical presentation, PSA testing and diagnosis 
Localized prostate cancers are in the vast majority asymptomatic, but symptoms such as 
nocturia, hesitancy and obstruction may be present, often due to concurrent benign prostatic 
hyperplasia (109). Metastatic disease can lead to bone pain, neurological symptoms from 
compression of the spinal cord and anemia (110). Prostate cancer is diagnosed by microscopy 
of core biopsies taken ultrasound-guided, with transrectal or transperineal approach, or of 
resected material following a transurethral resection of the prostate (TUR-P) or 
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cystoprostatectomy. MRI images may be of help in evaluating the risk of extra-prostatic 
cancer (111).  
PSA (official name: kallikrein-related peptidase 3) is a serine protease produced by 
prostate epithelium. PSA liquefies the semen and dissolves the cervical plug, hereby helping 
the sperm to swim freely. As the name implies, the production of PSA is highly specific to the 
prostate gland (112). A small amount of the produced PSA escapes into the blood circulation, 
and is subject to concentration measurements clinically. However, moderately elevated PSA 
levels are not specific to prostate cancer, but occur also as a result of benign prostatic 
hyperplasia and prostatitis (100). The normal range of PSA increases with higher age. It is 
difficult to set a definitive cut-off value, but levels below 3-4 ng/mL are often considered 
normal, although patients with aggressive cancer may have lower levels (100).  
The PSA test has been evaluated for prostate cancer screening, where patients without 
symptoms are tested to detect disease at an early stage in order to reduce mortality and 
improve future quality of life (113). In a European multicenter study, a reduction in prostate 
cancer mortality through PSA screening was demonstrated (3, 114). In an American study 
however, no statistically significant benefit on mortality was observed (115). In 2012, the 
Cochrane collaboration issued a review of the literature where they concluded that prostate 
cancer screening, defined as PSA testing with or without digital rectal examination, gave no 
significantly reduction in prostate-cancer specific mortality in an unsorted population (113). 
This is in line with conclusions from the U.S. Preventive Services Task Force (116), and 
Norwegian health authorities advises against PSA testing in an unsorted population (117). 
However, for patients with risk factors such as African-American heritage or family history 
with frequent diagnosis of prostate cancer and/or known mutations in susceptibility genes 
such as BRCA1 and BRCA2, the value of PSA testing potentially increases (116, 117).   
 
2.3.5 Staging and risk classification  
The disease stage is given by the tumor, node, metastasis (TNM) system (118). A description 
of the clinical TNM system is presented here: Tumor stages TX and T0 reflect a primary 
tumor that is either not possible to assess or find, respectively. Stage T1 indicates that the 
primary tumor is not palpable, but cancer is found by microscopy of tissue, either in material 
from TUR-P (T1a-b) or in a core biopsy after PSA testing (T1c). Stage T2 denotes a tumor 
that is palpable, but confined to the prostatic gland. In T2a less than half of one lobe is 
infiltrated, in T2b more than half one lobe is infiltrated, and in T2c both lobes are infiltrated 
(Figure 15). Stage T3a signifies a tumor growing out of the prostatic capsule, and T3b a tumor 
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growing into the seminal vesicles (Figure 15). In stage T4 the tumor has grown into adjacent 
organs such as the pelvis or bladder (Figure 15). 
All patients with lymph node metastases (N1) are high-risk patients, and there is 
controversy as to whether these patients are truly curable, despite pelvic lymphadenectomy 
(100). Patients with distant metastasis to non-regional lymph nodes or other sites are assigned 
M1 and are not candidates for curatively intended therapy (100). 
The gold standard for lymph node staging is pelvic lymphadenectomy, but magnetic 
resonance imaging (MRI) and computerized tomography (CT) may also be performed, albeit 
with lack of diagnostic accuracy (119). The use of risk nomograms has made pelvic 
lymphadenectomy superfluous prior to definitive therapy for patients at low risk of lymph 
node metastases (120). For M-staging, technetium scintigraphy is recommended in patients 
with PSA values above 20 ng/mL, or with Gleason score above 7a and clinical T-stage above 
2 (100).  
 
Figure 15: T-stages of prostate cancer. Adapted from (121), with permission. 
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Some patients diagnosed with prostate cancer will, due to indolent disease, never 
experience symptoms or disease progression, whereas others will have a rapid progression 
(122). The heterogeneity in disease aggressiveness prompts the need for reliable markers for 
correct management of prostate cancer patients (122). In general, low-risk patients could be 
candidates for surveillance and deferred treatment, whereas high-risk patients are candidates 
for combination of treatment modalities (100), as discussed below.  
Current risk estimation relies on clinicopathological parameters from studies of 
patients undergoing definite therapy in form of surgery or irradiation, where time to 
biochemical failure, defined as recurrence of PSA, was recorded (100). One of the most 
widely used risk classifications is the D’Amico risk model, based on Gleason score, PSA-
level and clinical T-stage at diagnosis (123). Another risk model is the University of 
California, San Francisco-Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score, 
where, in addition to the above mentioned parameters, percentage of positive core biopsies 
and patient age are included in the risk model (124).  
Methods for prostate cancer risk classification that have not yet reached the clinic 
include DNA, RNA and protein based biomarkers. A candidate DNA-based prognostic 
marker is the fusion gene TMPRRS2-ERG, which has shown variable independent prognostic 
value in different cohorts (125). Several RNA expression signatures have been developed for 
prognostication, but they are in general hampered by small cohort sizes and lack of 
independent validation (125). Moreover, gene signatures that show independent prognostic 
information have little overlap (126).  
Ki-67 is a protein biomarker that can be detected by immunohistochemistry. The 
protein is expressed in interphase cells, and Ki-67 is therefore a marker of proliferation. Ki-67 
staining of cancer tissue has been shown to add independent prognostic value in several 
prostate cancer cohorts, but due to factors like different cut-off values for positivity, it has still 
not reached clinical decision making (125). Other protein biomarkers that have been 
investigated, but not reached the clinic, include cell-cycle related proteins such as CDKN1A 
(p21) and apoptosis related markers such as BAX (127). 
 
 
2.3.6 Curative treatment modalities 
Choice of prostate cancer treatment modality relies on the TNM stage, age and co-morbidity, 
Gleason score, PSA-level and the patient’s own wishes. Two main curative treatment options 
are available in this category: Surgery and radiotherapy. The choice between these two is 
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highly controversial, as there are no randomized trials comparing them. Typically, a young 
and fit patient with localized disease will often be referred to surgery, while an older patient 
with locally-advanced disease and co-morbidity will be subjected to radiotherapy. There are 
however many exceptions from this rule.  
Long-term side-effects of both radiotherapy and surgery include impotence and 
incontinence. In addition, radiotherapy can induce rectal toxicity with diarrhea and bleeding, 
and surgery carries perioperative risks. Hence, a treatment form gaining ground the last years 
for low risk patients is active surveillance. Patients on active surveillance programs are 
followed closely with repeated digital rectal examinations, PSA measurements and biopsies, 
and definite treatment is deferred until signs of progression occur, but at a disease stage where 
cure is still possible (100).  
Surgical treatment of prostate cancer can be performed as open retropubic 
prostatectomy (ORP) or as robot-assisted laparoscopic prostatectomy (RALP). ORP has 
shown disease-specific and overall survival benefit in localized prostate cancer in one 
randomized trial as compared to watchful waiting (128), but this was not shown in another 
study (129). The first RALP was performed in 2000, and has since replaced more and more of 
the ORPs, also in Norway. RALP has shown to reduce peri-operative bleeding and incidence 
of blood transfusion, with comparable outcome as ORP (130). For high-risk prostate cancer 
patients, and where lymph node metastases are detected by imaging, prostatectomy combined 
with lymph node dissection should be performed, as this has been shown to prolong survival 
(100, 131). 
Radiotherapy for prostate cancer can be applied in several ways. The EAU guidelines 
recommend intensity-modified external beam radiotherapy (IMRT) with or without image-
guidance, combined with ADT for D’Amico intermediate and high-risk patients (100). Other 
treatment regimes include brachytherapy with low- or high-dose rate irradiation, alone or in 
combination with external beam radiotherapy and/or ADT. 
 
2.3.7 Palliative treatment modalities  
Palliative treatment forms can be offered patients that are no longer candidates for curative 
treatment, due to advanced disease stage on presentation or because of a watchful waiting 
strategy. Watchful waiting is another form of deferred treatment suitable in patients where 
cure is not the goal, due to factors like old age or co-morbidity. Any treatment is usually put 
on hold until signs of disease progression occurs (100).  
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A peculiarity of prostate cancer is the androgen dependence of the disease, described 
by Huggins and Hodges in 1941 (132). Since Huggins and Hodges work it has become 
evident that AR activity is important for viability, metabolism, proliferation and invasion of 
prostate cancer cells (50, 133, 134). As such, the backbone of palliative treatment is ADT, 
where the hypothalamus-pituitary-testicular axis is manipulated.  
One ADT approach is to perform bilateral orchiectomy, leaving the adrenal cortex 
alone in producing androgens. This is the most rapid way of reducing the testosterone level, 
and therefore remains the preferred treatment where a rapid reduction is wanted, as in spinal 
cord compression. Less drastic and irreversible methods are present however, in form of 
gonadotropin-releasing hormone (GnRH) agonists and antagonists, as well as steroidal and 
non-steroidal anti-androgens (100). GnRH agonists and antagonists will inhibit a stimulatory 
effect from the hypothalamus on the pituitary gland, thus reducing the level of luteinizing 
hormone and thereby decreasing the testosterone production by the testis. The GnRH agonists 
will however cause an initial flare-up period of higher testosterone levels, which could 
complicate a clinical situation of for instance skeletal pain. These complications can be 
counteracted by initially including the use of a non-steroidal anti-androgen, which are drugs 
that block the AR, thus interfering with androgen signaling (135).  
Eventually, the cancer will turn castration-resistant, i.e. progress despite ADT. In recent 
years new treatment modalities in form of immunotherapy, radio-immunotherapy and second-
line endocrine treatments have become available for castration-resistant disease, in addition to 
standard chemotherapy like docetaxel. The improvement in life-expectancy by these treatment 
modalities is however limited, and new strategies are highly warranted (100). 
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3. Summary of papers 
Paper I: The Hypoxia Marker Pimonidazole Reflects a Transcriptional Program Associated 
with Aggressive Prostate Cancer 
 
In Paper I we used pimonidazole immunohistochemistry and whole-genome gene expression 
analysis to identify transcriptional changes in hypoxic prostate cancer. We utilized material 
from 46 prostate cancer patients included in the clinical protocol, which was established as 
one of the thesis aims. Transcriptional changes associated with pimonidazole staining showed 
enrichment of the biological processes cell cycle, translation and cellular response to stress. 
We performed supervised gene set analysis with input gene lists encompassing these 
processes, in addition to lists of hypoxia-associated genes. A gene signature of 32 genes, all 
with a positive correlation to pimonidazole staining, was constructed. Nine of these genes 
were HIF1 targets. 
 Pimonidazole staining was associated with aggressive disease, demonstrated by 
increased presence of clinical stage T3 and lymph node metastasis in patients with high 
immunoscore. The pimonidazole gene signature was also associated with aggressive disease, 
in form of higher clinical T-stage and Gleason score and presence of lymph node metastasis in 
patients with high gene score. In addition, unsupervised clustering of the investigation cohort 
based on the pimonidazole gene signature showed association to presence of lymph node 
metastasis. Furthermore, expression of the pimonidazole-associated genes showed a positive 
correlation to the proliferation marker Ki67.   
To validate the association between our gene signature and aggressiveness, we 
procured two gene expression data sets from prostate cancer cohorts with information on 
Gleason score in the first, and survival in the second validation cohort. High expression of the 
pimonidazole gene signature was associated with Gleason score above 7a. Moreover, high 
expression was associated with reduced progression-free and overall survival in both uni- and 
multivariate analysis, the latter corrected for known aggressiveness markers such as Gleason 
score and TMPRSS2-ERG translocation. 
In conclusion, pimonidazole staining and associated transcriptional changes were 
related to an aggressive prostate cancer phenotype, including increased proliferation, as 
measured by Ki67. This may imply that genes involved in proliferation, DNA repair and 
hypoxia response contribute to prostate cancer aggressiveness, and that expression of these 
genes has the potential of being used as a prognostic biomarker.  
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Paper II: Hypoxia-independent Downregulation of Hypoxia-Inducible Factor 1 Targets by 
Androgen Deprivation Therapy in Prostate Cancer 
 
Since hypoxia is a risk factor in prostate cancer radiotherapy, a biomarker for tissue hypoxia 
during neo-adjuvant ADT would be helpful in timing of radiotherapy. To evaluate the use of 
HIF1α expression in this context, we analyzed HIF1α expression and gene transcription 
downstream of HIF1 in androgen exposed and androgen deprived CWR22 prostate cancer 
xenografts. In a previous study we had demonstrated no statistically significant differences in 
pimonidazole staining between these two conditions, which implied that the hypoxic fraction 
was comparable. To examine the clinical relevance of our findings, we also included HIF1α 
immunohistochemistry of a prostate cancer cohort subjected to ADT prior to radiotherapy.  
Whole-genome gene expression analysis revealed 1344 genes with more than two-fold 
expression change by ADT. Gene ontology analysis of these showed enrichment of the 
biological processes cell cycle, cellular response to stress, response to organic substance, 
steroid metabolic process, cell proliferation, monosaccharide metabolic process and apoptosis. 
Comparison of the differentially expressed genes with published lists of HIF1 targets, 
revealed that thirty-five downregulated and five upregulated HIF1 target genes were affected 
by ADT. The majority of HIF1 targets with transcriptional change by ADT were induced by 
hypoxia in androgen-responsive prostate cancer cell lines, supporting their role also in 
prostate cancer. Nineteen downregulated HIF1 targets were involved in the significant 
biological processes, most of them in energy metabolism. Four of these were shared AR and 
HIF1 targets, including genes encoding the regulatory glycolytic enzymes HK2, PFKFB3 and 
SLC2A1 (GLUT1).  
The downregulation of HIF1 targets by ADT was consistent with reduced HIF1  
expression in the androgen exposed xenografts, despite comparable hypoxic fractions. In 
addition, downregulation of HIF1  protein was seen in patient tumors going from androgen 
exposed to androgen deprived state. 
In conclusion, ADT may lead to decreased HIF1α protein expression irrespective of 
changes in hypoxic fraction. This was accompanied by downregulation of HIF1 signaling, 
including HIF1 target genes involved in the biological processes enriched by ADT, which 
suggests that HIF1 plays a role in the regressive phase under androgen deprivation. In this 
context, HIF1α downregulation seems to be a marker for androgen deprivation per se, rather 
than reduced hypoxic fraction.  
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Paper III: Vorinostat-Mediated Radiosensitization and Transcriptional Effects in Hypoxia-
Treated Prostate Cancer Cell Lines 
 
In Paper III we analyzed radiosensitizing effects of the HDAC inhibitor vorinostat on prostate 
cancer cell lines under hypoxic and normoxic conditions, and related these effects to changes 
in gene expression. We chose the DU 145, PC-3 and 22Rv1 prostate cancer cell lines since 
they had shown differential sensitivity to radiation and vorinostat.  
Following vorinostat exposure, a radiosensitizing effect was observed under normoxia 
and hypoxia in DU 145, at both 2 Gy and 5 Gy irradiation. Conversely, PC-3 showed only a 
trend towards radiosensitization. Vorinostat had radiosensitizing effects in 22Rv1 that reached 
statistical significance at 2 Gy under normoxic and 5 Gy under hypoxic conditions. Moreover, 
DU 145 showed a statistically significant accumulation of cells in G2/M phase, which may 
have contributed to the radiosensitizing effect. Significant changes in cell cycle distribution 
were not observed in PC-3. In 22Rv1, an accumulation of cells in G1 under both normoxia 
and hypoxia was observed, but this experiment lacked replicates, making the result uncertain. 
Hypoxia treatment in itself had no significant effects on the cell cycle distributions. 
To evaluate transcriptional effects by vorinostat, we selected DU 145 and PC-3, which 
showed the largest difference in radiosensitization. Based on the gene expression data, we 
found that DU 145 showed enrichment of several biological processes, among them cell cycle 
and cellular response to stress. PC-3 had fewer enriched processes. In DU 145, a reduced 
expression of HIF1α was seen after vorinostat exposure under both normoxic and hypoxic 
conditions, whereas this was not observed in PC-3 or 22Rv1. To provide evidences that the 
reduced HIF1α protein level was followed by a change in HIF1 signaling, we performed a 
network analysis on HIF1 targets and their protein interactions, where the interaction partners 
were selected among the genes that showed significantly altered gene expression by 
vorinostat. DU 145 had larger interaction networks than PC-3, involving a higher number of 
both direct targets and interaction partners. The networks showed similarity between 
normoxia and hypoxia treatment classes, especially for DU 145.  
In conclusion, vorinostat treatment of prostate cancer cell lines showed promising 
radiosensitizing properties under hypoxic and normoxic conditions, suggesting that vorinostat 
has a potential as a method to overcome hypoxia related radiation resistance in prostate 
cancers. We demonstrated changes in HIF1α protein expression and HIF1 transcriptional 
program after vorinostat treatment, and propose that HIF1α or its target genes may have a role 
as biomarkers for the radiosensitizing effects.  
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4. Evaluation of materials and methods 
  
4.1 Clinical protocols 
4.1.1 The Funcprost protocol  
The clinical protocol established as part of this thesis is “MRI for assessment of hypoxia-
induced prostate cancer aggressiveness”, in short termed Funcprost (ClinicalTrials.gov: 
NCT01464216). The aim of the Funcprost study is to evaluate hypoxia driven prostate cancer 
aggressiveness, and in Paper I, some of the material from the study was analyzed. The 
Funcprost protocol encompasses work by several scientists and clinicians, and the author of 
this thesis had the role as study coordinator, which comprised practical organization of 
investigations, inclusion of patients, pimonidazole infusion, bone marrow aspiration and 
collection of cancer biopsies. The Funcprost study was approved by the regional ethics 
committee and the institutional board. Patients received a formal description of the study in 
lay language and gave signed consent to participation. We organized the protocol in 
accordance with the Norwegian act on medical and health research (the Health Research Act) 
from 2008. An unofficial English translation of the law is given by The Faculty of Law, 
University of Oslo (136).  
The inclusion criterion in the Funcprost study was biopsy confirmed prostatic 
adenocarcinoma in a patient referred for surgery. In addition, patients should have 
intermediate or high risk disease according to D’Amico classification (123). These wide 
criteria caused inclusion of patients within a broad range in aggressiveness, which increased 
the dynamics in hypoxic fraction across the tumors, and the possibility of finding associations 
to biological and clinical parameters.  
Exclusion criteria included previous cancer forms, contraindications to MRI contrast 
agents, allergies to substances chemically related to pimonidazole, for instance metronidazole, 
or previous treatment for prostate cancer such as radiation or hormonal manipulation. Bone 
marrow aspirates were performed to search for disseminated tumor cells at time of surgery. 
Due to this, we wanted to exclude patients with a previous cancer diagnosis, as the etiology of 
a positive test otherwise could be equivocal. Patients with history of previous prostate cancer 
treatments were excluded since we aimed to analyze molecular biology of prostate cancer 
unaffected by androgen deprivation or radiation therapy.  
All patients underwent MRI examination within one week prior to surgery. The MRI 
protocol included functional sequences in form of diffusion weighted MRI, dynamic contrast 
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enhanced MRI and blood oxygen level dependent MRI (Fig. 16). In the work included in this 
thesis, the MRI images were used in prediction of index tumor localization to improve correct 
biobanking of biopsies. With guidance from these images, biobanking was performed with a 
punch biopsy knife after manual identification of cancer foci (Figure 16). We harvested two 
tumor biopsies from the suspected index tumor site, in addition to a biopsy from normal 
tissue. The use of a surgical cohort allowed us to evaluate the whole-mount section from the 
punch biopsy site, thus ensuring that we had taken the sample from the index tumor. This 
would not be possible in a radiotherapy cohort.  
From October 2011 to July 2012 we included 53 prostate cancer patients referred for 
RALP at the Norwegian Radium Hospital, Oslo University Hospital. Unfortunately, we have 
not made a record of patients unwilling to participate, but this fraction is estimated to 
approximately 10 %. Of the 53 patients, 46 had fresh frozen punch biopsies which fulfilled 
our criteria for inclusion, and material from this group was analyzed in Paper I. Of the seven 
patients not included, one patient had postponed surgery, thus, biopsies were not taken. The 
remaining six patients had either biopsies not taken from the index tumor or index tumor 
biopsies that did not fulfill our criteria of at least 75% malignant glands and less than 50 % 
stroma.  
Exclusion of patients with the lowest fraction of malignant glands may have enriched 
our investigation cohort for high tumor grades (107) and thereby probably reduced the 
variation in the biological data. Moreover, this led to less number of patients in the analysis 
and lower power in the statistical tests. Conversely, inclusion of biopsies with lower cancer 
cell fraction would have obscured the gene expression signal from tumor cells. 
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Figure 16: Flow diagram of investigations in the Funcprost project relevant for this thesis. 
MRI images courtesy of Knut Håkon Hole, MD, and printed with permission. Abbreviations: 
T2: T2 weighted image. DCE: Dynamic contrast-enhanced MRI with T2 image overlaid, 
ADC: Apparent diffusion coefficient with T2 image overlaid, DW: Diffusion-weighted image 
with T2 overlaid. 
  
Pimonidazole infusion and time to surgery 
Median time from pimonidazole infusion to total free dissection of the prostate was 
19.4 hours with range 13.5-24.8 hours (Figure 16; Paper I). In the study protocol, planned 
time from infusion to surgery was 12-24 hours, which is close to what was achieved, and in 
line with other clinical studies, where time from infusion to surgery or biopsy typically has 
been 10-24 hours (137) or 16-24 hours (138, 139). For the patients included in Paper I, 
pimonidazole was available only for intravenous administration demanding access to infusion 
devises. Thus, the time points for pimonidazole administration were limited, and we were 
only able to administer pimonidazole to 43 of the 53 patients in the cohort. This corresponded 
to 39 of the 46 patients included in Paper I. In recent months however, pimonidazole has 
become available in oral formulations, facilitating adaptation of drug administration to time of 
surgery the following day. This does however demand a comparison of staining intensities 
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between the two methods before possible pooling of data. Hence, we chose to analyze the 
transcriptional program reflected by pimonidazole concurrently to the change from 
intravenous to oral administration.  
With data available for 32 patients, we found no statistically significant correlation 
between pimonidazole immunoscore and time from pimonidazole infusion to surgery         
(r=-0.20; P=0.26), showing that the difference in time to surgery among the patients was not 
large enough to influence the score significantly (Paper I). Considering the limited power due 
to a low number of patients, we cannot, however, exclude that a long time from infusion to 
surgery could lead to lower pimonidazole score.  
 
Ischemia time 
The gene expression analysis in Paper I was based on material from fresh frozen tumor 
biopsies (Fig. 16). During surgery, the prostate will be gradually dissected free from the 
vasculature and subsequently placed in a bag inside the abdominal cavity, while the 
anastomosis between the bladder and the urethra is made. Loss of oxygen supply with 
following cellular reactions could pose a problem for the gene expression analysis. 
Consequently, it was a goal to keep time from total free dissection to snap-freezing as short as 
possible. For 36 of the patients, this time period; i.e. ischemia time, was recorded, showing 
range from 37-70 minutes and median 50 minutes (Figure 16; Paper I).  
We searched for correlation between the pimonidazole gene score and ischemia time, 
and for differences in ischemia time between patients belonging to two different gene 
expression clusters. None of these correlation analyses showed any relation between ischemia 
time and gene expression data (Paper I). This is in accordance with previous work by Dash 
and co-workers, who studied changes in global gene expression in prostate cancer relative to 
ischemia time after radical prostatectomy (140). They found that only 0.6% of the 
investigated genes showed significant alterations in gene expression after one hour ischemia 
time before snap-freezing (140). Similar results have been obtained in breast cancer, where 
only a small fraction of genes had significant expression changes after the first hour (141). As 
such, with the aim of comparing gene expression between patients, we concluded that a 
median ischemia time of 50 minutes with range 37-70 minutes was acceptable. 
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Punch biopsies versus whole mount prostatectomy sections 
Our protocol enabled analysis of pimonidazole staining in whole mount prostate sections and 
punch biopsies from the same patients (Figure 16). In identification of a transcriptional 
program represented by pimonidazole, we used the immunoscore from the punch biopsies to 
ensure full representativeness. For further analysis in the Funcprost protocol, such as 
pimonidazole in relation to MRI parameters and bone marrow micrometastases, it is important 
that the pimonidazole score in the punch biopsies reflects staining of the entire index tumor, 
represented by the whole mount section. 
 
Figure 17: Pimonidazole immunoscores in punch biopsies versus whole mount sections. 
N=39, with 6 dots identical between the punch biopsies and the whole mount sections. 
 
The statistically significant association between pimonidazole immunoscores of the 
punch biopsies and whole mount sections was 0.58 (Figure 17). As such, it seemed that the 
hypoxic status in the punch biopsies to a large degree reflected the hypoxic status in the whole 
mount sections. However, the association between punch biopsy and whole mount 
pimonidazole immunostaining is not perfect. Thus, there is intra-tumor heterogeneity in 
pimonidazole staining and variation in hypoxia in different parts of the tumor. This enables 
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future analysis of molecular alterations in different sub-areas of the same tumor showing 
different pimonidazole staining intensities. 
 
4.1.2 The ADT protocol  
In Paper II material from a clinical protocol on patients receiving conformal radiotherapy for 
prostate cancer was utilized (Figure 18). As part of the protocol, all patients received neo-
adjuvant ADT consisting of goserelin acetate and bicalutamide 3-6 months prior to radiation. 
In preparation for radiotherapy, two biopsies from the prostate were taken with trans-rectal 
approach. In addition, we summoned the diagnostic, androgen exposed biopsies from the 
referring hospitals (Figure 18). This allowed us to compare the expression of HIF1α in 
androgen exposed (AE biopsy) and androgen deprived (AD biopsy) tumors from the same 
patients. For analysis, we used the needle biopsy with highest Gleason score from the 
androgen exposed state, considered to represent the index tumor, and the biopsy with largest 
tumor focus in the androgen deprived group. 
 
 
 
Figure 18: Flow chart of the ADT protocol. Following diagnostic biopsies at the referring 
hospitals, in Paper II referred to as AE biopsy, patients were subjected to androgen 
deprivation. Three to six months later, study biopsies, in Paper II referred to as AD biopsy, 
were taken.  
 
Disadvantages of the approach in Paper II compared to the prostatectomy cohort in 
Paper I, where whole mount sections were available, include questionable representativeness 
of biopsies. Expression of proteins may be heterogeneous, and analysis on a small needle 
biopsy without knowledge of the surrounding tissue, could be insufficient to give a general 
view of tumor protein expression. On the other hand, the core biopsy is the available material 
prior to prostate cancer treatment. Thus, if the goal is protein markers for aggressiveness 
upfront of treatment, analysis of such biopsies in study protocols is desirable. The use of 
formalin fixed paraffin embedded material from the diagnostic biopsies made analysis of gene 
expression more difficult. This hampered the analyses in Paper II, where investigation of 
HIF1-dependent gene expression in prostate cancer patients would have been of interest. 
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4.2 The CWR22 prostate cancer xenograft model system 
In Paper II we generated an experimental in vivo model for the effect of ADT on prostate 
cancer by implanting tissue fragments of the androgen-sensitive CWR22 prostate cancer 
xenograft subcutaneously in the flank of male Balb/c nude mice aged 6-8 weeks. To reduce 
differences in the testosterone concentration among the animals, a 12.5 mg sustained-release 
testosterone pellet was inserted subcutaneously in the neck region. CWR22 was originally 
harvested from the primary tumor of a patient with high-grade and high-stage prostate cancer 
(Gleason score 9, M+ disease) (142). The model is known to express PSA and be sensitive to 
ADT (143). In a previous study, this xenograft model had shown no statistically significant 
differences in hypoxic fraction between androgen exposed and androgen deprived xenografts 
at a diameter of 8 mm (144). Thus, to study hypoxia independent HIF1 signaling, this model 
seemed suitable.  
 ADT was performed by surgical castration at fixed tumor volumes, and the 
testosterone pellet was concurrently removed. We analyzed concentration levels of the 
androgen dependent protein PSA to ensure that castration was efficiently performed. The 
androgen exposed and androgen deprived PSA levels were 39 and 10 μg/L, respectively 
(145). Moreover, in another study on the same model system, where the tumors were allowed 
to regress further before sacrifice, PSA values approaching zero were demonstrated (146), 
showing a similar PSA pattern as prostate cancer patients on ADT. By comparing hypoxic 
fractions, transcriptional changes and HIF1α expression at identical volumes in androgen 
exposed and androgen deprived xenografts, we counteracted the potential effects of tumor 
volume on gene and protein expression.  
 
4.3 Prostate cancer cell line models  
In vitro cell cultures or cell lines are often used as models for cancer disease, due to 
characteristics such as immortality and rapid replication, which ensure easy access to 
material. In addition, they provide a reproducible and homogeneous model system. 
Disadvantages include lack of stromal interaction, unphysiological growth conditions and 
deviations from their parental disease/cellular system due to long-term passage on plastic.  
Four prostate cancer derived cell lines were used in the thesis: 22Rv1 (147), LNCaP 
(148), DU 145 (149) and PC-3 (150). The cell lines were identity confirmed by short tandem 
repeat profiling, using Powerplex 16  (151). The only cell line of primary origin is 22Rv1, 
which is derived from the prostate cancer xenograft CWR22-R, i.e. CWR22 recurring after 
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castration. 22Rv1 is reported to be weakly stimulated by androgens (147), and is as such 
androgen responsive. LNCaP is derived from cancer cells metastasized to a lymph node in a 
patient undergoing ADT for prostate cancer. Both 22Rv1 and LNCaP contain functional AR 
(152). However, the receptor is truncated in LNCaP, which makes the cells more susceptible 
to unspecific stimulation through different ligands. LNCaP is also known to turn into 
androgen independence after a series of passages, and for this reason only passages below 40 
were used in our studies (153). DU 145 and PC-3 are cell lines derived from brain and bone 
metastases, respectively, and are considered to show no expression of AR (152). The cell lines 
therefore seemed to be appropriate in vitro model systems for androgen responsive (22Rv1, 
LNCaP; Papers I, II) and non-responsive (DU 145, PC-3; Papers I, III) tumors. 
 
4.3.1 Model for tumor hypoxia 
A model for hypoxia was created by the use of a humidified hypoxia chamber with integrated 
control of O2, CO2 and N2 concentrations. Cell lines were plated and allowed to fasten before 
hypoxia exposure. As a model for chronic hypoxia we exposed the cells to 0.2 % oxygen for 
24 hours. From our own laboratory, we had in vitro evidence of relevant hypoxia signaling 
with induction of HIF1α, as well as hypoxia induced radioresistance at this oxygen level. The 
level is also relevant for the study of hypoxia induced genetic instability (66) and has been 
found in vivo by the use of Eppendorf needles (154). Thus, the model seemed relevant in 
exploring both hypoxia induced radioresistance and disease aggressiveness. 
In Paper I hypoxia inducible genes were assessed by treating the four prostate cancer 
cell lines with 0.2 % oxygen for 24 hours. Genes that showed a two-fold change in expression 
as compared to control cells in at least two of four cell lines were identified. This provided us 
with a comprehensive list of hypoxia responsive genes that could be compared to gene 
expression in prostate cancer in patients. We included all four cell lines to cover 
representation of different cancer biologies. In Paper II we exposed the androgen responsive 
cell lines 22Rv1 and LNCaP to hypoxia to support the prostate cancer relevance of HIF1 
targets that were previously derived from chromatin immunoprecipitation studies on breast 
and hepatocellulary carcinoma cell lines (155, 156). Since we analyzed gene expression 
changes by ADT in a xenograft system with functional AR, we included only the two cell 
lines which showed androgen responsiveness. In Paper III we treated the prostate cancer cell 
lines 22Rv1, PC-3 and DU 145 with 0.2 % hypoxia for 24 hours prior to irradiation to 
investigate hypoxia induced radioresistance. We included these cell lines to cover a range of 
vorinostat- and radiation sensitivity. To avoid reoxygenation prior to radiation, closed caps on 
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the cell flasks were used when we transported the flasks from the hypoxia chamber to the 
radiation machine located in the adjacent room.  
To disclose possible errors, the hypoxia chamber log file containing oxygen detector 
readings was checked following all experiments. However, we did not include oxygen 
concentration measurements from the cell cultures exposed to oxygen, but we assumed that it 
reached a steady state after 24 hours. Reassuringly, radioresistance was observed in the 
hypoxia-treated cell lines, in addition to expected changes in gene expression as reported in 
the literature.  
 
4.3.2 Methods for evaluation of radiation response 
Following radiation, cells may repair the damaged DNA and progress through S and M phases 
successfully, as described above in section 2.1.1. Alternatively, they may induce the apoptotic 
program and undergo controlled cell death. However, immediate apoptosis is probably not the 
main mechanism for cell death in solid tumors following radiation (157). Often, unsuccessful 
repair and so-called mitotic catastrophe, where daughter cells inherit DNA with alterations 
incompatible with life, dominate the response. Secondarily, apoptosis or necrosis, i.e. 
uncoordinated cell death, may occur, or cell senescence, i.e. permanent conversion to a non-
proliferative state (30).  
The clonogenic assay examines the ability of single cells to form colonies of fifty cells 
or more in a tissue culture, termed the clonogenic capacity, and it takes all forms of cell death 
into account. The assay can be performed on cancer cell lines to evaluate efficacy of different 
forms of treatments (157). The clonogenic capacity of treated cells and control cells is 
compared, with the ratio between them, the surviving fraction, taken as a measure of 
treatment efficacy (30). To ensure that clones contained fifty cells or more, microscopy of 
candidate clones was performed both in control and treated samples. To avoid bias, a 
colleague unrelated to the study counted several cell plates blinded to treatment groups 
(Figure 19). In general, she gained a lower number of clones, but the surviving fractions 
remained the same, and in accordance with the conclusions of the paper. 
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Figure 19: Number of colonies counted by two different investigators, where one was blinded 
to treatment class. 
 
In the 3D clonogenic assay a different approach in guiding the cut-off for colonies had 
to be applied, since the cells were lumped together in a sphere. Thus, as an assumption of 
sphere diameter corresponding to fifty cells, we stained the nuclei with either SYBR Gold or 
Hoechst, and counted number of nuclei in stacked microscopy immunofluorescence pictures. 
The sphere diameter corresponding to at least fifty cells was regarded as being the limit for a 
colony. 
 
 
4.4 Detection of tumor hypoxia  
There are several methods for detecting hypoxia in a tissue, including direct measurement of 
pO2 using Eppendorf electrodes. This has been undertaken in several tumor types, including 
prostate cancer, and remains the gold standard for hypoxia detection (154, 158). 
Disadvantages include the inability of measuring pO2 in tumors not accessible from the 
surface, its invasiveness and the lack of comparison between morphology and oxygen 
measurements. As a consequence, the pO2 may by a mistake be read in non-cancerous tissue, 
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potentially diluting relevant measurements. This is especially important in cancer forms 
where normal tissue is interspersed in the tumor, as in prostate cancer.   
Endogenous and exogenous tissue markers have been used for hypoxia quantification 
by immunohistochemical approaches. In contrast to pO2 measurements, use of 
immunohistochemistry allows direct comparison of hypoxia markers and morphology. 
Endogenous markers are typically proteins where the expression is induced by hypoxia, for 
instance HIF1α, solute carrier family 2, member 1 (SLC2A1, alias GLUT1) and carbonic 
anhydrase 9 (CA9). Disadvantages using endogenous markers include influence of factors 
other than hypoxia that can affect protein expression levels. For instance can HIF1α levels be 
dependent on AR activity (Paper II, (78)) and CA9 levels dependent on microenvironment 
acidity (159), independent of hypoxia.  
These limitations are avoided by the use of exogenous markers, where the antigen 
detected by immunohistochemistry is given to the patient or research animal prior to sampling 
of material. In both Paper I and II, we used the 2-nitroimidazole pimonidazole as hypoxia 
biomarker. Pimonidazole, as other 2-nitroimidazoles, forms adducts with amino acids, 
peptides and proteins in hypoxic cells, with oxygen levels for binding are shown to be below 
10 mmHg or 1.3 % oxygen (Figure 20, (160)). Pimonidazole has been shown to mark oxygen 
gradients independent of relevant enzyme activity (161). Compared to other 2-
nitroimidazoles, pimonidazole is of limited toxicity, as doses required for hypoxia detection 
are low.  Disadvantages include the possibility that binding of 2-nitroimidazoles may happen 
irrespective of hypoxia, as demonstrated in a study of head-and-neck squamous cell 
carcinoma, where pimonidazole staining under oxic conditions was demonstrated in areas of 
keratinization (162). It should also be noted that no significant relationship between 
pimonidazole staining and hypoxia as measured by Eppendorf needles was found in head-
and-neck squamous cell carcinoma (137), questioning the comparability of results achieved 
with the two methods.  
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Figure 20: Pimonidazole staining gradient in a prostate cancer section with necrotic area 
(encircled).  
 
4.5 Gene expression analysis 
In this thesis we have studied gene expression in prostate cancer tumors, xenografts and cell 
lines by whole-genome Illumina HT12 v4.0 gene expression bead arrays containing 
approximately 47,300 probes. The approach gives an overview of the transcriptome, i.e. the 
complete set of mRNA transcripts, at a specific time point. Hence, rather than studying single 
genes, we explore expression of all genes at the same time.  Whole-genome analysis makes 
unsupervised approaches possible, where computer programs can, in an unbiased fashion, 
analyze differential gene expression between tumors and after specific interventions of cell 
lines, or identify gene expressions related to biological and clinical information. In particular, 
transcriptional alterations in all genes involved in the same biological process or signaling 
pathway can be found, thereby providing strong evidences for a change in tumor phenotypes. 
This was demonstrated by the gene ontology and gene set analyses in our studies, and the 
further exploration of the HIF1- and AR pathways. However, although gene expression often 
is an indication of the encoded protein level, this must be confirmed in separate analyses, as 
discussed below. In addition, neither regulation of translation nor enzyme activity is provided. 
The Illumina method provides reliable results, as was demonstrated in Paper II, where 
we applied quantitative real-time polymerase chain reaction (qRT PCR) as technical 
validation of the Illumina data. The threshold level for each gene was set automatically by the 
software in the logarithmic part of the PCR curve, and the gene expression levels were 
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analyzed with the delta-delta method, using B2M as reference gene. The PCR results showed 
a strong correlation to the Illumina data, although the genes selected for the validation 
analysis had expressions within a narrow range (Paper II). 
A prerequisite for obtaining reliable data is, however, that high quality RNA is 
utilized. In particular, in analysis of clinical material obtained after surgery, a concern is the 
instability of the RNA molecule and a possible degradation before the samples are frozen. To 
investigate whether this could have occurred in our study, we recorded the ischemia time, as 
described above in section 4.1.1 and in Paper I. 
 
Downstream analysis of gene expression data 
When analyzing 47,300 transcripts at the same time, the risk of obtaining false positive results 
is imminent. As such, we corrected for multiple testing using the Benjamini-Hochberg 
algorithm provided in the software (163, 164). We used the Linear Models for Microarray 
data (LIMMA) analysis to identify differentially regulated genes between patient samples 
(Paper I) and between treated and untreated cell lines (Paper III). In short, LIMMA uses 
moderated t-statistics to find differentially expressed genes in dichotomized microarray 
datasets (165). The software provides p-values corrected for multiple testing, which we 
utilized in Paper III. In Paper I a nominal p-value of 0.05 was applied, to achieve enough 
genes for the further downstream analyses. In this paper, we included validation of the final 
results, justifying the use of this approach.  
To explore the functional meaning of the LIMMA results, several analysis tools were 
applied. In all three papers, the gene lists were imported into the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) software (164). The DAVID software offers 
several analyses based on the gene ontology (GO) term, which is decided for each gene  by a 
consortium working to unify the annotation of different gene products in relation to their 
known biological process, cellular component and molecular function (166). Significance 
Analysis of Microarrays for Gene Sets (SAM-GS) (167) is another approach where 
enrichment of predefined gene sets, reflecting known signaling pathways or biological 
processes, were explored by comparing the gene expression profiles of pimonidazole positive 
and negative tumors (Paper I). Finally, to explore to what extent the HIF1 signaling pathway 
was changed by vorinostat treatment in Paper III, we utilized network analysis where 
interactions between proteins encoded by the differentially expressed HIF1 target genes and 
other genes in the gene list were identified and visualized (168). The functional analysis tools 
are of utmost importance for the interpretation of gene lists. All methods, however, rely on the 
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current knowledge of gene function, signaling pathways or protein interactions, which is a 
major limitation of these approaches. 
 
Prostate cancer validation cohorts 
In Paper I gene expression data from two prostate cancer cohorts were used to validate results 
from the investigation cohort. As analysis of gene expression data carries the risk of over-
fitting results to the data, and the use of independent validation cohorts is highly valuable. 
This approach is facilitated through the Gene Expression Omnibus (GEO) database, where 
research groups deposit gene expression data together with relevant clinical information. We 
used two gene expression data sets, one from a prostatectomy patient series (GSE32571; 
(169)) and one from a watchful waiting patient group (GSE16560; (170)) .  
A pitfall of this approach may include differences in the gene expression platform, 
making comparison between the cohorts difficult. In GSE32571 however, the Illumina bead 
array platform was used, which allowed us to extract identical probes as used in the 
investigation cohort. In GSE16560, the cDNA-mediated annealing, selection, ligation and 
extension platform with only 6100 genes was used. Hence, just 19 of 32 genes in the 
pimonidazole gene signature were present in this data set, and a separate analysis was 
required to ensure that this subgroup of genes satisfactorily reflected the pimonidazole 
staining (Paper I). Reassuringly, expression of every gene in our signature showed correlation 
to pimonidazole. Moreover, unsupervised clustering of the investigation cohort based on the 
19 genes produced two clusters where the pimonidazole immunoscore tended to be higher in 
the cluster with high gene expression. In addition, the score based on these genes was 
significantly higher for the pimonidazole positive tumors. This showed that patients clustered 
in a way that still had connection to pimonidazole staining, although only 19 of the genes 
were used, allowing us to draw conclusions based on the GSE16560 validation cohort. 
Another important aspect in using validation cohorts from the GEO database is the 
availability of supportive clinico-pathological information. Researchers that upload data to the 
GEO database add a file with information on these aspects, but the detail level in this file may 
vary. In GSE32571, the endpoint was Gleason score in the prostatectomy specimen above 7a, 
thus dividing the cohort in two groups based on a well-defined aggressiveness marker. 
Unfortunately, follow-up data was not available in this cohort. The GSE16560 data set 
enabled analysis of pimonidazole-associated gene expression in relation to progression-free 
and overall survival. As the patients were in a watchful waiting regime, no treatment details 
were needed. The strength of this cohort was the long follow-up time of up to 30 years, 
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whereas methodological weaknesses include that patients were diagnosed in the pre-PSA era 
and they had all stage T1a-b tumors, i.e. non-palpable tumors discovered on TUR-P due to 
lower urinary tract symptoms. This could question the representativeness to patients 
diagnosed today. However, aiming for a validation of the pimonidazole gene signature in 
relation to disease aggressiveness, a cohort of patients not receiving definite treatment was 
ideal.  
 
AR and HIF1 target genes 
In this thesis we utilized published lists of HIF1 (Paper I-III) and AR (Paper I, II) target genes 
to explore signaling through these transcription factors in hypoxic prostate tumors, and 
following androgen deprivation of prostate cancer xenografts and hypoxia and vorinostat 
treatments of prostate cancer cell lines (50, 155, 156). The target lists were published in 
papers using chromatin immunoprecipitation to analyze transcription factor target sites in the 
genome, combined with whole-genome transcriptional analysis following interventions (171). 
The AR targets had been found by stimulating the androgen sensitive cell lines VCaP and 
LNCaP with androgens (50). We included only genes with elements found to bind AR that 
were either upregulated or downregulated by androgens (50). However, functional binding 
sites of androgens may differ in various prostate cancer models, and the AR target list may 
therefore not have been the correct one for our analysis of gene expression changes in 
CWR22 xenografts following androgen deprivation. On the other hand, the list was generated 
based on the union of expression profiles from two different androgen sensitive cell lines, 
increasing the sensitivity. 
For identification of direct HIF1 targets, results from two individual chromatin 
immunoprecipitation analyses were included (155, 156). As for AR, we included genes with 
an altered expression following hypoxia treatment of cell lines. A weakness of this approach 
was the use of cell lines derived from other cancer types than prostate cancer to generate the 
list, which may reduce its relevance since the hypoxia response may be cell-specific (172). To 
ensure that the targets of interest were of relevance for prostate cancer, we therefore ensured 
that they were regulated in prostate cancer cell lines exposed to hypoxia (Paper II).  
 
4.6 Protein expression analysis 
For protein studies, we performed Western blot analysis of selected proteins and 
immunohistochemistry of HIF1α and Ki67. In addition, we used immunohistochemistry to 
assess the binding of pimonidazole in the tumors. Western blot and immunohistochemistry are 
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two different techniques using antibody binding and detection systems for protein 
quantification with different strengths and weaknesses.  
 Western blot was performed by separating whole cell lysates by sodium dodecyl 
sulfate polyacrylamide-gel electrophoresis (SDS-PAGE) as a function of molecular size. We 
used ladder to control the size and gamma-tubulin as loading control. As such, one can read 
the expression signal in relation to molecular size, disclosing unspecific antibody binding. A 
weakness regarding Western blot, however, is the inability to distinguish between cancer and 
normal tissue. For this reason, the technique was applied only on cell lines, whereas 
immunohistochemistry was used on material from xenografts and patients. 
By immunohistochemistry, distribution of a protein between normal and cancerous 
cells, as well as distribution within different cellular compartments, can be studied. The 
technique can, however, not distinguish between specific and unspecific binding. As such, the 
use of negative controls is important. In Paper I, we included negative controls for the 
pimonidazole antibody using both irrelevant antibodies on a specimen containing 
pimonidazole adducts, and applying anti-pimonidazole antibody on a patient who received no 
pimonidazole. In addition, irrelevant antibodies for Ki67 were applied. None of these negative 
controls had detectable immunostaining. We therefore concluded that the Ki67 and 
pimonidazole data were reliable.  
In Paper II, negative control for the HIF1α antibody showed staining of the 
cytoplasmic compartment in cancer cells. We therefore interpreted only staining in the nuclear 
compartment as true positive in the analysis of HIF1α expression. Of importance for the 
validation of this antibody was also the observation that Western blots showed positive results 
only at a molecular size corresponding to the known size of the HIF1α protein, suggesting that 
unspecific binding was a minor problem. 
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5. Discussion of results  
 
5.1 Pimonidazole as marker for aggressive, hypoxic prostate cancer 
Hypoxia, defined by a pimonidazole positive fraction above 10%, was detected in almost half 
of the tumors included in the Funcprost protocol (Paper I), in line with previous work 
suggesting that hypoxia is a common finding in prostate cancer (154, 173). The degree of 
hypoxia differed considerably both between and within the tumors; in some cases the whole 
tumor showed strong pimonidazole staining, whereas in others no staining was observed. 
Correspondingly, staining variation was also found in a study by Carnell and co-workers 
(139). PO2 measurements by electrodes, traditionally considered the gold standard of hypoxia 
detection (38), have also shown heterogeneity in the oxygen level across prostate tumors (154, 
173). This large difference in hypoxic fraction between the tumors increases the chance of 
finding biological and clinical features associated with the hypoxic phenotype, and eases a 
potential use in the clinic.  
We observed positive association between pimonidazole immunoscore and both 
presence of clinical T3 tumors and lymph node metastasis at diagnosis. This relationship to 
aggressive features is in line with the study by Carnell and co-workers, where an association 
between increased pimonidazole staining and high Gleason score was observed (139). The 
correlating endpoints differed between the studies (Paper I and (139)), possibly due to the 
limited number of included patients, 39 and 37 respectively, leading to low statistical power. 
However, presence of clinical T3 stage, lymph node metastasis and high Gleason score are all 
well validated aggressiveness markers, with high impact on prostate cancer patient outcome 
(100, 123). All together, these results support a relationship between increased pimonidazole 
staining and cancer aggressiveness and encourage accomplishment of larger studies to clarify 
the role of pimonidazole as hypoxia marker in clinical decision making.  
 
5.2 Transcriptional program reflected by pimonidazole staining 
To achieve a better understanding of the molecular phenotype reflected by pimonidazole 
staining, a whole genome transcriptional analysis was performed (Paper I). Pimonidazole 
positive prostate cancers had enrichment of the biological processes cell cycle, translation and 
cellular response to stress, and gene lists encompassing proliferation, DNA repair and hypoxia 
were the most significantly enriched in the following gene set analysis (Paper I). Hypoxia-
induced changes in gene expression vary among different cell types (174). Correspondingly, 
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the hypoxia responsive genes in the transcriptional program showed greatest similarity with 
the hypoxia gene sets derived from prostate cancer cell lines, whereas those derived from 
other cancer types were less significant in the gene set analysis (Paper I, (175-180)). An 
explanation might be that AR regulates many of the same pathways as are activated under 
hypoxia (50). This was demonstrated in Paper II, where genes in classical hypoxia response 
pathways like glycolysis showed massive downregulation following androgen deprivation 
despite comparable hypoxic fractions. Possibly, androgen dependent regulation of such 
pathways in prostate cancer outweighs the effect from a hypoxic tumor environment and 
decreases the transcriptional differences between hypoxic and less hypoxic tumors. Hence, no 
enrichment of the biological processes related to glycolysis was seen in pimonidazole positive 
tumors in our work (Paper I), in contrast to the findings following androgen deprivation 
(Paper II). It is also important to keep the oxygen level for pimonidazole staining in mind, 
which is higher than both radiobiologically relevant hypoxia and the limit used in many 
studies to identify hypoxia gene sets (58, 181). Thus, this could explain why the 
transcriptional program associated with pimonidazole staining differ from others identified 
through prediction analysis of outcome after radiotherapy (175). 
The transcriptional program of pimonidazole positive tumors seemed to represent a 
condition where cells were both hypoxic and proliferative (Paper I). As such, oxygen levels 
reflected by pimonidazole staining were probably sufficiently high for cell proliferation to 
occur. Proliferation and hypoxia-related tissue remodeling phenotypes have previously been 
studied with regard to prostate cancer aggressiveness by Markert and co-workers, where a set 
of curated gene expression profiles from several cancer forms were analyzed, including the 
same data set used for validation in our work (Paper I, (16, 170)). In line with our results, 
combined proliferation and hypoxia-related remodeling gene sets showed a stronger 
prognostic value in prostate cancer than the hypoxia-related remodeling or proliferation gene 
sets alone. This was also the case for cancers of the brain and ovary, pointing to generality of 
the findings (16). It therefore seems that a phenotype comprising both proliferation and 
hypoxia is particular aggressive not only for prostate cancer, but for several cancer types. 
Moreover, our work suggests that this phenotype is reflected by pimonidazole staining in 
prostate cancer.  
 
5.3 Role of HIF1 in the transcriptional program and cancer aggressiveness  
Although HIF1 is often upregulated in aggressive cancers (80), we observed no statistically 
significant associations between HIF1α expression in diagnostic biopsies from the ADT 
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cohort and Gleason score, clinical T stage, lymph node metastasis or other clinicopathological 
parameters (Paper II). However, the low number of patients reduced the power of our 
analysis, which may explain this lack of associations. HIF1α expression has been investigated 
by several groups in both surgery and radiotherapy cohorts, albeit with differing results (80, 
182). In particular, the observation by Weber et al. of decreased biochemical failure rate 
following radiotherapy for prostate cancers with high HIF1α expression is unexpected (182), 
and points to a more complex regulation of the protein rather than reflection of tumor oxygen 
levels. Hence, underlying biology reflected by differential HIF1α expression in prostate 
cancer is not clear (82). Our work shows that androgen deprivation (Paper II) and HDAC 
inhibition (Paper III) can cause HIF1α downregulation irrespective of hypoxic fraction. 
HIF1α could reflect other mechanisms important for disease aggressiveness, for instance AR 
or mTOR activity (78). These observations adds up to the increasing data on hypoxia-
independent regulatory mechanisms of HIF1 activity in general (183). HIF1α is therefore 
probably not a good biomarker of hypoxia in prostate cancer.    
HIF1 could, though, play a role in the transcriptional program activated in aggressive, 
hypoxic prostate tumors. In the pimonidazole gene signature, nine of thirty-two genes were 
known HIF1 targets (Paper I). This high fraction indicates that genes under regulatory control 
by HIF1 may have a role in adaptation to hypoxia in prostate cancer. The genes included 
FOXM1 and BIRC5, which are involved in apoptosis suppression (184, 185). Thus, tumors 
with high pimonidazole gene score could have activation of anti-apoptotic signaling 
controlled by HIF1. Moreover, expression of the two genes showed correlation to Ki67 
staining (Paper I), in line with the role of HIF1 in cell survival and proliferation. Even though 
metabolism as biological process was not significantly enriched in the pimonidazole positive 
tumors, the HIF1 target PKM, which is involved in metabolism, was part of the pimonidazole 
gene score. This points to altered energy metabolism in pimonidazole positive tumors, in line 
with bona fide biological alterations in hypoxia (37).  
 
 
5.4 HIF1 signaling and response to ADT and vorinostat 
By pimonidazole staining, we had previously demonstrated that the hypoxic fraction was 
comparable between androgen exposed and androgen deprived state in the CWR22 xenograft 
at 8 mm diameter (144). This provided us with the opportunity to study possible hypoxia-
independent changes in HIF1 signaling following androgen deprivation. Increased 
oxygenation of prostate cancer following neo-adjuvant ADT prior to radiation therapy could 
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have clinical implications and had been a matter of debate in the literature (186-188). ADT 
led to reduced expression of key regulatory enzymes in glycolysis (Paper II), in agreement 
with the study by Massie and co-workers, where AR activity was shown to have a pivotal role 
in energy metabolism (50). Moreover, we found that key glycolytic enzymes, such as HK2, 
PFKFB3, and PKM2 were targets of both AR and HIF1 (50, 155, 156). This may imply that 
part of the ADT effect on energy metabolism is through reduced HIF1 signaling and occurs 
independently of changes in the hypoxic fraction of the tumor. 
In Paper III, the DU 145 cell line showed downregulation of HIF1α expression and 
changes in HIF1 dependent signaling following vorinostat treatment under both normoxia and 
hypoxia. Simultaneously, these alterations were not seen in PC-3, where radiosensitizing 
effects of vorinostat were minimal. This points to possible involvements of HIF1 signaling in 
the vorinostat effect related to radiosensitization. The differential radiosensitizing effect of 
vorinostat on the cell lines was a result of differences in the genetic and epigenetic 
background between DU 145 and PC-3. Other research groups have reported that DU 145 is 
more sensitive than PC-3 to vorinostat as single modality (189, 190), but our findings showed 
that the effect by vorinostat on clonogenic survival was comparable between the cell lines 
(Paper III). In addition to different assay endpoints, the diverging results between the studies 
may be due to differences in treatment dose and duration of vorinostat exposure, as these 
factors are known to affect vorinostat sensitivity (190).  
In general, HDAC inhibitors are known to cause HIF1α downregulation, including 
both the baseline and hypoxia-inducible values. The HDAC inhibitor PCI-24781 was shown 
to modulate HIF1α expression in lymphoma cell lines, where incubation for 24 hours led to 
downregulation of HIF1α and increased apoptosis (191). The HDAC inhibitor TSA reduced 
basal and hypoxia-induced HIF1α protein levels in human tongue squamous cell carcinoma 
cells in vitro without affecting the mRNA levels (192). Vorinostat has been shown to reduce 
HIF1α expression in lung carcinoma cell lines (193), and in macrophages following hypoxic 
stress (194). Interestingly, Chong and co-workers noticed an increase in the PHD2 enzyme 
following vorinostat treatment of macrophages, pointing to a possible post-translational 
downregulation of HIF1α (194). As discussed, HIF1 is known to be important for survival, 
proliferation and metastasis of cancer cells in general, and for hypoxic cancer cells in 
particular (37). Hence, one could speculate that the downregulation of HIF1α in DU 145 
phenotypically weakened the cells to such a degree that a second blow by radiation caused the 
apparent radiosensitizing effect. Correspondingly, since vorinostat at 1 μM concentration did 
not cause downregulation of HIF1α in PC-3, a radiosensitizing effect of similar magnitude 
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was not observed. Another possible mechanism is through direct function of HIF1α in the 
DNA damage response. Interestingly, DNA-PKcs, XRCC5 and XRCC6 (KU 80 and KU 70, 
respectively) in NHEJ have been shown to be under transcriptional control by HIF1, and 
HIF1α can also modify ATM activation following DSBs (195).  
 
 
5.5 Hypoxia-directed strategies for improved prostate cancer patient care 
In this thesis we observed that patients with hypoxic tumors, as measured by the pimonidazole 
gene score, had aggressive disease with reduced survival in a watchful waiting cohort (Paper 
I). Other research groups have shown that patients with low prostate cancer pO2 have 
significant risk of relapse, metastasis and death despite curatively intended radiotherapy (4, 
5). In intermediate and high-risk disease, it has been shown that the combination of 
radiotherapy and ADT increase the disease-specific and overall survival compared to 
radiotherapy alone (196-198). In line with this, our gene signature may potentially aid in 
selecting patients at increased risk of relapse, where intensified treatment is needed. 
Interestingly, Milosevic and co-workers demonstrated that ADT improves the oxygenation of 
prostate tissue and related this to the increased radiotherapy efficacy (187). As such, neo-
adjuvant ADT could be a possible treatment strategy for hypoxic prostate tumors in general, 
prior to radiation. For timing of radiotherapy with regard to reoxygenation, it would be useful 
to have a biomarker for tissue hypoxia. However, we demonstrated that HIF1α is probably not 
a good hypoxia biomarker during ADT (Paper II). 
Other possibilities following identification of hypoxic tumors would be to introduce 
hypoxia-targeted treatment, as has been successfully done in head and neck cancer by 
utilization of the drug nimorazole (178).  Another method for specific targeting is introduction 
of so-called contextual synthetic lethality, where the hypoxic tumor microenvironment or 
activated pathways in hypoxic tumors is targeted (66). In this thesis, we demonstrate that 
vorinostat decreased the surviving fraction at 2 Gy and 5 Gy under both normoxia and 
hypoxia in DU 145 (Paper III). In addition, statistically significant radiosensitizing effects 
were seen in 22Rv1. As such, vorinostat could be a promising drug in high-risk prostate 
cancer in general, and in hypoxic prostate cancer especially. However, the drug has been 
shown to induce side effects, and other HDAC inhibitors may provide better improvements 
(199). 
Widespread PSA testing has had the positive effect of identifying high-risk patients at 
a stage where they are still candidates for curative treatment. However, the other side of the 
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coin is the identification of patients with low-risk disease who would never experience 
symptoms from prostate cancer (200). If all these patients were treated with definite treatment 
forms, unnecessary side effects would be the result. Appreciating this problem, active 
surveillance has become a management strategy, after introduction by Choo and co-workers 
in 2002 (200, 201). Enrollment of patients with low-risk disease to active surveillance has 
been performed in cohort studies, with low rate of progression and cancer-specific death (100, 
202). One challenge could be to include other patient groups to active surveillance protocols, 
for instance a subgroup of patients with Gleason score 7a. In this effort, additional markers to 
distinguish between lethal and indolent cancer is needed. Interestingly, our gene signature 
gives independent prognostic information in a watchful waiting series (Paper I). However, a 
potential value of prognostic information should be validated in a relevant patient group from 
the post-PSA era.  
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6. Conclusions and future perspectives 
 
“The challenge to physicians today is to identify the minority of men with aggressive, 
localized prostate cancer with a natural history that can be altered by definitive local 
therapy, while sparing the remainder the morbidity of unnecessary treatment” 
Zelefsky, Eastham, Sartor and Kantoff;  
Chapter 40.6 in Cancer 
Principles and Practice of Oncology, 2008,  
edited by DeVita, Lawrence and Rosenberg. 
 
 
Improved patient selection for definitive treatment is highly warranted in prostate 
cancer. Correspondingly, patients identified as having high risk of relapse are candidates for 
new, intensified treatment forms. In prostate cancer, hypoxia is related to disease 
aggressiveness and especially to relapse following radiotherapy. As such, hypoxia is both a 
potential prognostic biomarker and a target for intervention. Thus, the overall aim of this 
thesis was to investigate whole-genome transcriptional programs in prostate cancer related to 
hypoxia and treatment interventions. 
 To conclude, we have presented a gene signature characteristic of hypoxic prostate 
cancer. Expression level of the genes showed independent, prognostic value when corrected 
for known markers of disease aggressiveness in a patient cohort not receiving treatment. This 
is promising, and motivates for validation studies in patient cohorts from the post-PSA era 
subjected to active surveillance, surgery or radiotherapy. In addition, increased insight into the 
molecular background of aggressive, hypoxic tumors was achieved that could reveal key 
pathways in aggressive disease, thus opening up for directed treatment of hypoxic prostate 
cancer. Hence, we are currently recruiting more patients in the Funcprost protocol and follow-
up data are collected. In addition, the protocol includes evaluation of other hypoxia markers, 
including multiparametrical MRI, which allows repeat, non-invasive measurements to be 
taken.  
 Patients identified at high risk of relapse by established prognostic markers, and 
perhaps especially patients with hypoxic tumors, should receive improved treatment. This 
could be performed by refining current treatment strategies. One possibility would be to 
adjust radiotherapy initiation to the point where neo-adjuvant ADT had improved tumor 
oxygenation. In this thesis we provide proof-of-principle evidence that expression of HIF1α is 
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not a good marker for the changes in hypoxic fraction by ADT, since HIF1α expression and 
HIF1 dependent gene transcription were found to be affected by ADT independently of 
hypoxia. A more compelling strategy could be to introduce imaging parameters to evaluate 
tissue hypoxia during a course of neo-adjuvant ADT. 
Another way of treating hypoxic, aggressive tumors would be to intensify the 
treatment. We provide pre-clinical evidence that the HDAC inhibitor vorinostat has 
radiosensitizing effects, with sustained effect under experimental, hypoxic conditions. Thus, 
radiosensitization by HDAC inhibitors is a possible strategy to overcome treatment failure 
due to hypoxic tumors. However, the effect was variable between cell lines, and further 
experimental in vivo validation should include search for biomarkers. 
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